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Abstract 
This thesis describes three studies with flbrate drugs in Chinese 
patients with hyperlipidaemia. The causes and consequences of 
hyperlipidaemia are initially discussed and the characteristics of the patient 
study group are described. The patients involved mainly have combined 
hyperlipidaemia and they may be classified as having familial combined 
hyperlipidaemia or hypertriglyceridaemia and the metabolic syndrome 
involving insulin resistance may be a major underlying factor. 
In the first study, a dose-titration study with gemfibrozil, there were 
increasing falls in semm triglyceride levels of 71%, 76% and 79% but the 
effect on semm total cholesterol was limited and not obviously dose-
dependent. Serum HDL-cholesterol rose slightly but semm apolipoprotein AI 
tended to fall and apolipoprotein B tended to rise. The levels of semm 
lipoprotein Lp(a) showed wide variation with no consistent effect. 
There was no elevation of liver enzymes or creatine kinase and glucose 
levels remained unchanged. The dose of 300 mg bd gemfibrozil produced 
marked reductions in triglyceride levels and may be an adequate dose in many 
patients as the higher doses had little additional effect, except producing 
further slight reduction of triglycerides in some cases. 
In the second study with a 900 mg tablet formulation of gemfibrozil, 4 
patients withdrew due to constipation, abdominal discomfort or dizziness but 
the drug was well-tolerated by the other 20 patients. The effects on the lipid 
profile were similar after 4, 8 and 12 weeks of treatment and comparable to the 
three doses of gemfibrozil used in the first study. The major effect was 
xiii 
reduction of triglycerides with increases of HDL-cholesterol of up to 19 % but 
there was little change in total cholesterol and LDL-cholesterol appeared to 
rise in some patients. Apolipoprotein B was slightly reduced and 
apolipoprotein AI remained the same but lipoprotein Lp(a) tended to rise. 
Again there was no change in indices of glycaemic control and no adverse 
effects on liver enzymes or creatine kinase. 
The third study involved a slow release tablet of bezafibrate 400 mg 
daily in 23 Chinese patients which was generally well tolerated. Again, 
triglyceride levels were reduced, HDL-cholesterol increased and total 
cholesterol was unaltered. Fasting blood glucose and glycosylated 
haemoglobin were not significantly altered, but fibrinogen levels were 
reduced. 
Overall, the response in these Chinese patients was similar to that 
previously described in Caucasians. The effects on LDL-cholesterol and 
apolipoprotein B differed from our findings in some previous studies, probably 
because of different types of hyperlipidaemia in the patients studied rather 
than any ethnic difference in response. There was no effect on the indices of 
glycaemic control studied with either drug but fibrinogen was reduced with 








































Chapter 1 Introduction 1 
Chapter I Introduction 
1.1. Lipids: their nature and function in man 
Lipids are water - insoluble organic molecules characterized by the hydrocarbon 
nature of a major portion of their structure. Cholesterol is a steroid alcohol which is an 
essential structural component of membranes and a precursor of steroid hormones and 
bile acids. It is derived from the diet and endogenous synthesis. Fatty acids have 
hydrocarbon chains classified according to the number of carbon atoms and number of 
double bonds. They are a source of energy and precursors of complex lipids and other 
essential molecules. Fatty acids combine with cholesterol to produce cholesterol esters 
e.g. cholesterol linoleate. 
Glycerol can combine with 3 fatty acids to form triglycerides which are stored in 
adipose tissue as an energy source. If the terminal hydroxyl group of glycerol is esterified 
to a polar phosphate-containing molecule, rather than a fatty acid, a phospholipid results 
e.g. lecithin from choline phosphate. Phospholipids play a structural role in cell 
membranes and in the surface layer of lipoprotein complexes. 
All the plasma lipids, except free fatty acids (FFAs), are in the form of 
lipoproteins which are spherical particles with a polar outer shell of apolipoproteins, 
phospholipids and free cholesterol and a non-polar core of triglycerides and cholesterol 
esters. Lipoprotein particles vary in size, in their lipid constituents and in their specific 
apolipoproteins (Table 1.1). Lipoproteins can be separated into 5 major classes by 
ultracentrifugation or electrophoresis (Thompson, 1994). The classes may be further 
subdivided by size, density or apolipoprotein content e.g. HDL into HDL� and HDL3. 
Apolipoproteins have a structural role and facilitate metabolism of lipoproteins by 
activating enzymes or binding to receptors. Genetic variations in the apolipoproteins may 
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result in various degrees of abnormality. Some polymorphisms such as the E4 allele of 
apoprotein E (apo E) will produce a minor increase in cholesterol and may contribute to 
polygenic hypercholesterolaemia (Davignon et al. 1988). 
Lipoprotein(a) is a type ofLDL particle with an additional apolipoprotein, apo(a), 
bound to apoB100 by disulphide bonds. The size of apo(a) varies due to genetic 
polymorphism (Utermann et al. 1987) and it exhibits close homology with plasminogen. 
It appears to be thrombogenic by interfering with the conversion of plasminogen to 
plasmin and it is also atherogenic, so high levels increase the risk ofCHD. 
1.2. Lipid metabolism 
Ingested fats are transported via lymphatics to the blood stream as triglycerides in 
chylomicrons. These initially contain apo B48, which is of intestinal origin, along with 
apoAI, AII and AIV and then acquire apoE and apoCII from HDL particles in exchange 
for apo AI. Their triglycerides are hydrolysed by an enzyme, lipoprotein lipase (LPL), 
which is bound to the capillary endothelium by heparan sulphate chains. This is activated 
by apoCII on the chylomicron surface. The resulting chylomicron remnants are taken up 
by hepatocytes by binding through apoE mainly to the LDL receptor-related protein 
(LRP) and to a lesser extent to the LDL receptor (LDL-R). Free fatty acids are taken up 
by tissues at the site of hydrolysis and used as a source of energy or stored (Thompson, 
1994). 
Some fatty acids are esterified in the liver to triglycerides and secreted in VLDL 
particles which contain apoB 100, apoE and apoC. These are also metabolised by 
lipoprotein lipase resulting transiently in IDL particles which are taken up by the liver or 
converted by hepatic lipase into LDL particles. These are taken up mainly by the liver 
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but also by peripheral tissues to provide a supply of cholesterol. This occurs by apoB 100 
linking with the LDL-R. LDL is the main cholesterol-carrying lipoprotein. 
Nascent HDL particles are formed in the intestine and the liver, and take up 
excess cholesterol from the tissues which is esterified by lecithin cholesterol 
acyltransferase (LCAT) and then transferred to the core resulting in HDL3 particles. 
These supply cholesterol esters to VLDL and LDL via cholesterol ester transfer protein 
(CEPT) and they receive triglycerides and apoC from VLDL to become HDL2 particles. 
These are converted back to HDL3 by hepatic lipase. 
1.3. The definition and classification of hyperlipidaemia 
1.3.1. The definition of hyperlipidaemia 
Hyperlipidaemia may be defined as being present when the blood lipid levels are 
higher than the normal values. The normal values for blood lipids vary in different 
populations and what may be considered normal in one country may be quite abnormal 
in another. The term dyslipidaemia may be used to describe the condition when lipid 
levels are abnormal, but not all abnormally high. This especially applies to high density 
lipoprotein (HDL) cholesterol where low levels are known to be associated with 
increased cardiovascular risk. Dyslipidaemia typically refers to the pattem of lipid 
abnormalities characterised by high triglyceride levels, low HDL-cholesterol levels and 
an abnormal pattem oflow density lipoprotein (LDL) particles. This pattem is commonly 
found in diabetes (Betteridge, 1994). 
The numerical definition of hyperlipidaemia or dyslipidaemia is normally based 
upon the distribution of lipid levels in the population and abnormal levels would be 

















































































































































































































































































































































































































































Chapter 1 Introduction 5 
The lipid levels in the population of Hong Kong have previously not been studied on an 
adequate basis to be certain of the true population figures so the Chemical Pathology 
laboratory at the Prince of Wales Hospital uses figures based on normal values from 
Westem populations. The desirable and abnormal ranges quoted by the Chemical 
Pathology laboratory are: 
Total cholesterol: desirable <5.2, borderline high 5.2 - 6.2, high > 6.2 mmol /1 
LDL-cholesterol: desirable <3.4, borderline high 3.4 - 4.1, high > 4.1 mmol /1 
Triglycerides: desirable < 2.0 mmol /1 
HDL -cholesterol: desirable > 1.0 mmol /1 for men and > 1.2 mmol /1 for women. 
1.3.2. Lipid levels and diet in Hong Kong and other Chinese populations 
Longitudinal data are limited, but cholesterol levels appear to be increasing in many 
Chinese populations although they have not reached the values seen in most westem 
countries. Average total cholesterol levels in Hong Kong adults were 5.1 and 5.0 nrnioVl in 
men and women respectively in a recent population survey (Janus, 1997) and similar figures 
of5.2 and 5.3 mmol/1 for men and women were reported in Taiwan (Pan and Chiang, 1995). 
Total and LDL-cholesterol increase with age as seen in Caucasian populations. Levels were 
higher at about 5.7-5.9 mmoVl in the Chinese population of Singapore in the 1980s (Hughes 
et al, 1990 a,b) but have subsequently fallen. 
Smaller surveys in Hong Kong 3-4 years ago (Table 1.2) reported slightly higher 
levels ofcholesterol but these may have had some selection bias and it is unlikely that lipid 
levels are falling at present in Hong Kong or Taiwan. Indeed, a study of lipid levels in seven 
year old children in Hong Kong showed average cholesterol levels of 4.6 mmoVl which are 
higher than most westem countries (Leung et al. 1994). Fat represented 30% of the total 
dietary energy intake in the children and the polyunsaturated fat / saturated fat (P/S) ratio 
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was low at 0.69. A similar fat intake was found in the survey of Hong Kong adults and fat 
and cholesterol intake tended to be higher and potassium intake lower in younger than in 
older subjects (Janus, 1997). The diet in Hong Kong may still be changing rapidly, 
particularly in the younger generation. 
In Taiwan a five fold increase in the intake of fat and cholesterol was seen from 1950 
to 1987 and the proportion ofenergy from dietary fat rose from 16% to 36% but the P/S ratio 
was apparently maintained at 1.3 over that period which might help to explain the favourable 
blood lipid profile and low CHD mortality (Pan and Chiang, 1995). This high P/S ratio is 
thought to result from the use of soybean oil as the major cooking oil. A high intake of soy 
protein may also improve plasma lipid levels and soy contains large amounts of 
phytoestrogens and other compounds which may help to protect from CHD. Other 
constituents of the Chinese diet such as tea may be rich sources of antioxidants and some 
teas, especially green tea, may also improve the lipid profile. 
The latest lipid levels from the population survey in Hong Kong show slightly lower 
total cholesterol and LDL-cholesterol than the earlier surveys but HDL-cholesterol levels are 
slightly lower and triglycerides slightly higher. This could be related to the prevalence of 
non-insulin dependent diabetes mellitus Q^IDDM) which is increasing at an alarming rate in 
Asian countries and has nearly reached 10% of the adult population of Hong Kong. In 
subjects aged 65-74 years diabetes and impaired glucose tolerance were present in 22% and 
25% of men and 29% and 26% of women respectively (Janus, 1997), so over half the older 
population probably have some degree of glucose intolerance. The associated dyslipidaemia 
increases along with the progression from impaired glucose tolerance to definite NIDDM 
(Lau et al, 1993) and also as the degree of albuminuria increases in Chinese NIDDM patients 
(Chan et al, 1996). 
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Table 1.2 Lipid levels in Hong Kong from the recent population survey and some 
previous studies. Values are mean (SD) or {SEM} in mmol /1. 
Age groups - yrs.  
Reference 20-29 30-39 40-49 50-59 >60 All ages 
Total Cholesterol 
Men To&Donnan,1988 4.58 4.93 5.13 5.19 5.06 
(0.98) (0.98) (1.03) (1.25) (1.16) 
Lau et al, 1993 4.72 5.09 5.34 5.52 5.70 5.3 
(1.07) (1.01) (0.89) (0.94) (0.92) (0.98) 
Fongetal, 1994 5.02 5.55 5.58 5.59 5.87 5.45* 
{0.13} {0.11} {0.14} {0.13} {0.16} (1.05) 
Janus, 1997 4.6 5.0 5.3 5.2 5.3 5.1(0.03} 
Women To & Donnan, 1988 4 J 6 449 4 ^ ^ ^ 
(1.07) (0.98) (0.91) (1.31) (1.38) 
Lau et al, 1993 4.55 4.59 4.72 5.09 5.66 4.79 
(0.60) (0.85) (0.85) (0.88) (1.11) (0.89) 
Fong et al, 1994 5.02 4.97 5.36 6.04 6.45 
{0.11} {0.09} {0.10} {0.13} {0.13} 
Janus, 1997 4.3 4.65 4.95 5.6 5.8 5.0 {0.03} 
Triglycerides 
Men Lauetal, 1993 1.08 1.20 1.43 1.44 1.45 1.33 
(0.58) (0.82) (0.98) (0.71) (0.77) (0.86) 
Fongetal, 1994 0.87 1.22 1.46 1.54 1.37 1.11* 
{1.06} {1.07} {1.09} {1.08} {1.10} (1.78) 
Janus, 1997 1.1 1.4 1.5 1.3 1.4 1-4(0.03} 
Women Lauetal, 1993 069 0 ^ ^ ^07 L32 OM 
(0.30) (0.33) (0.66) (0.79) (0.78) (0.64) 
Fong et al, 1994 0.74 0.88 0.99 1.40 1.47 
{1.06} {1.06} {1.04} {1.05} {1.06} 
Janus, 1997 0.8 0.85 1.05 1.25 1.65 1.1(0.02} 
HDL-cholesterol 
Men Lauetal, 1993 1.22 1.28 1.23 1.22 1.26 1.25 
(0.28) (0.30) (0.31) (0.37) (0.38) (0.31) 
Fong etal, 1994 1.31 1.25 1.19 1.17 1.29 1.34* 
{0.04} {0.03} {0.04} {0.04} {0.05} (0.34) 
Janus, 1997 1.16 1.13 1.13 1.19 1.21 1.15(0.01} 
Women Lau et al, 1993 L ^ L6l L47 L52 133 L53 
{0.29) (0.32) (0.37) (0.46) (0.31) (0.38) 
Fong et al, 1994 1.51 1.45 1.43 1.34 1.31 
{0.04} {0.04} {0.03} {0.04} {0.04} 
Janus, 1997 1.43 1.36 1.37 1.33 1.27 1.35(0.01} 
LDL-cholesterol 
Men Lauetal, 1993 3.01 3.27 3.45 3.63 3.78 3.39 
(1.05) (0.92) (0.89) (0.92) (0.99) (0.94) 
Fong et al, 1994 3.28 3.65 .56 3.57 3.86 3.53* 
{0.13} {0.10} {0.13} {0.12} {0.12} (1.0) 
Janus, 1997 2.9 3.25 3.40 3.45 3.50 3.30(0.02} 
Women Lau et al, 1993 1 ^ 1 ^ ^ ^ ^ 3 ^ 
(0.55) (0.78) (0.82) (0.84) (1.08) (0.84) 
Fong et al, 1994 3.13 3.03 3.44 3.99 4.37 
{0.11} {0.09} {0.09} {0.13} {0.12} 
Janus, 1997 2.50 2.85 3.10 3.70 3.70 3.20(0.02} 
* Mean for all ages from Fong et al, 1994 is for both sexes combined. 
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1.3.3. The classification ofhyperlipidaemia 
The hyperlipidaemias can be divided into two major groups, primary and secondary. 
1.3.4. The primary hyperlipidaemias: Genetic disorders oflipid metabolism 
Mutations may affect enzymes, receptors or other processes which can interfere with 
lipid metabolism and result in dyslipidaemia. They may be inherited as an autosomal 
dominant such as familial hypercholesterolaemia or as autosomal recessive like the 
homozygous deficiency of lipoprotein lipase or apo-CII giving rise to 
hyperchylomicronaemia. Others, like common hypercholesterolaemia, appear to result from a 
polygenic inheritance (Thompson, 1990; Oberman, 1992). 
The primary hyperlipidaemias were originally classified by Fredrickson into 5 
phenotypic groups according to the elevated lipoprotein fraction. This was subsequently 
modified by the World Health Organization (WHO) dividing Type II into IIa and IIb. More 
recently identification of underlying genetic mutations has produced a more meaningful 
classification which demonstrates that particular phenotypes could be due to more than one 
underlying genetic defect interacting with environmental factors (Table 1.3). 
1.3.5. The secondary causes of hyperlipidaemia 
The main causes of secondary hyperlipidaemia are listed in Table 1.4 (Thompson, 
1990; Oberman, 1992). In the studies described in the subsequent Chapters the major factors 
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Table 1.4 Main causes ofsecondary hyperlipidaemia 
Main lipid increased HDL-C change  
Disease: 
.Diabetes TG ^ 
.Obesity TG+Chol >^  
.Nephrotic syndrome Chol +TG ^ 
.Chronic renal failure TG + Chol ^ 
• Liver disease Cholesterol 
• Anorexia nervosa TG 
.Hypothyroidism Chol + TG 
.Myeloma Chol + TG 
Drug: 
• Alcohol abuse TG 
• Thiazides TG+Chol Nor>i' 
.Beta-blockers TG >^  
.Steroids Cholesterol 
• Retinoids TG 
• Oral contraceptives TG 
• Cyclosporin Cholesterol 
.Phenytoin HDL -C 个 
1.4. The signs and symptoms ofhyperlipidaemia 
1.4.1. The signs of hyperlipidaemia 
1.4.1.1. Comeal arcus 
Corneal arcus developing before the age of 60 is often associated with 
hypercholesterolaemia. It is also more common in smokers than non-smokers and may be a 
marker for increased risk of CHD independent of smoking or cholesterol levels (Thompson, 
1990). The extent of the arcus varies from initially affecting only the upper margin of the 
comea then upper and lower margins and finally forming a complete ring. The colour varies 
from dark grey to white. The extent and age of onset of the arcus do not correlate very well 
with plasma cholesterol but tend to be consistent in affected members of families with familial 
hypercholesterolaemia (FH). It reflects deposition of lipoprotein materials within the comea 
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and is virtually irreversible. A different and more severe form of comeal opacity is described 
as fish eye disease. This is seen in patients with familial lecithin cholesterol acyltransferase 
(LCAT) deficiency. 
1.4.1.2. Xanthomata 
These are yellowish lipid deposit. Tendon xanthomata are typical of heterozygous FH 
but also occur in other primary or secondary hyperlipidaemias with sustained elevations of 
cholesterol of about twice the normal level. These localised or diffuse deposits of lipid 
material are most often found in the achilles tendons and the extensor tendons on the dorsum 
ofthe hands and less frequently in other areas such as the patellar tendons (Thompson, 1990). 
They will resolve with effective lipid-lowering treatment. There may be a predilection for 
sites which are subject to mild repeated trauma and this is also the case for tuberous 
xanthomata which occur in the skin over boney prominence such as the elbows and knees or 
on the hands. These are found in cases with more severe hypercholesterolaemia such as 
homozygous FH, remnant hyperlipidaemia or certain chronic secondary hyperlipidaemias 
such as that seen in primary biliary cirrhosis. 
Deposits oforange xanthomatous material in the palmar creases are seen in some cases 
of remnant hyperlipidaemia. Severe hypertriglyceridaemia is associated with eruptive 
xanthomata which consist of macular deposits often on the buttocks or back (Thompson, 
1990). 
1.4.1.3. Xanthelasmata 
Xanthelasmata are deposits of lipid material in the eyelids and are even less specific 
for hyperlipidaemia than comeal arcus. They commonly occur in subjects with 
hypercholesterelaemia but other more subtle lipid abnormalities may be found such as raised 
VLDL cholesterol or increased LDL: HDL cholesterol ratio. A family has been described 
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where a mutation in the scavenger receptor resulted in increased uptake of LDL into 
macrophages to produce foam cells with extensive deposits of xanthelsmata and xanthomata. 
(Thompson, 1990). 
1.4.2. The symptoms ofhyperlipidaemia 
Hyperlipidaemia itself is usually asymptomatic unless cutaneous stigmata develop. 
Achilles tendonitis may occur (Thompson, 1990). More commonly, the patients with mild 
hyperlipidaemia will present with symptoms of the complications which are caused by the 
vascular insufficiency such as angina, myocardial infarction, intermittent claudication, 
transient ischaemic attacks cerebrovascular accidents, mesenteric ischaemia or severe 
abdominal pain from acute pancreatitis. 
1.5. Investigations and monitoring ofhyperlipidaemia during studies of drug treatment 
1 .5 .1 . The clinical investigation ofhyperlipidaemia 
The clinical assessment of hyperlipidaemia includes taking the history, physical 
examination and laboratory tests. The history taking consists of present history, past history, 
paying attention to any condition which may relate to hyperlipidaemia, family history trying 
to find out if similar illnesses occur in other family members and lastly social history asking 
particularly about dietary habits, alcohol intake and smoking. A full physical examination is 
performed include looking for any signs related to hyperlipidaemia and attempting to find out 
if any other organs are abnormal which may lead to secondary hyperlipidaemia. In addition, 
the patient's height, body weight, hip and waist circumference and blood pressure are also 
measured. Afterwards, blood is taken to measure the fasting plasma lipid profile, glucose, 
liver function tests, urate, fibrinogen, HbAlc, renal function and complete blood picture as 
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initial screening tests to assess the severity of the condition to look for underlying causes and 
to assess overall cardiovascular risk. 
1.5.2. The clinical and laboratory monitoring ofhyperlipidaemia 
1.5.2.1. The clinical monitoring ofhyperlipidaemia 
During the course of lipid studies, the patients are asked about any complaint which 
may be due to the complication of the hyperlipidaemia or the side effect of the drugs. The 
signs of the hyperlipidaemia are observed to see whether the signs such as xanthomata or 
xanthelasmata become smaller than before treatment. The blood pressure, body weight, hip 
and waist circumference are also measured every four weeks during the study. 
1.5.2.2. The laboratory monitoring of hyperlipidaemia 
The blood is taken every four weeks during the study. The plasma basic lipid profile, 
fasting plasma glucose, liver function, renal function and complete blood picture are 
monitored. The more detailed lipid profile, HbAlc, fibrinogen and insulin sensitivity tests may 
be done at the beginning and the end of the study. These tests would monitor the change of 
plasma lipid levels and the side effect of the drugs. 
1.6. The therapy of hyperlipidaemia 
Treatment ofhyperlipidaemia is required to prevent the development ofcomplications. 
Nowadays, there are several methods available for the treatment of hyperlipidaemia . They 
include dietary therapy, physical exercise, control of other risk factors such as obesity, 
hypertension, diabetes mellitus and smoking, dmg therapy, extracorporeal removal of 
lipoprotein, surgical procedures and gene replacement therapy (Thompson, 1990). The last 
three methods are reserved for radical therapy of refractory hyperlipidaemia, usually due to 
genetic disorders such as homozygous familial hypercholesterolaemia. Among these 
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methods, dietary therapy is the most common method employed for mild to moderate 
hyperlipidaemia and drug therapy is commonly used for the treatment of moderate to severe 
hyperlipidaemia. Drugs can effectively control the blood lipid levels although they cannot 
cure the hyperlipidaemia which will return if drug therapy is stopped. 
Table 1.5. Lipid-lowering drugs 
Drug class and daily dose Effects on lipid fractions 
LDL-cholesterol HDL-C TG  
HMG-CoA reductase inhibitors l20^30% T2-12% UO-20% 
• fluvastatin 20-40 mg od 
• lovastatin 20-80 mg od 
• pravastatin 10-40 mg od 
• simvastatin 5-40 mg od 
Bile acid sequestrants il5-30% t3-5o/o Neutral / increase 
• cholestyramine 4 g od - 8g bd 
• colestipol 5 g od -15 g bd 
Fibrates ilO-15%* tl5-25% 丄 3 5 - 5 0 % 
• bezafibrate SR 400 mg od 
• gemfibrozil 3 00-600mg bd 
• fenofibrate 200 mg od -100 mg tds 
• ciprofibrate 100-200 mg od 
Nicotinic acid and derivatives ilO-25% tl5-35o/o il5-30% 
• nicotinic acid 0.5-1 g tds 
• acipimox 250 mg bd-qds 
• nicofuranose 0.5-1 g tds 
Probucol ilO-15% i20-25% Neutral 
• probucol 0.5 g bd 
Omega-3 marine oils Neutral / increase Neutral >^ 0-80o/o 
• maxepa 5-15 g / day  
LDL-cholesterol = LDL-cholesterol; HDL-C = HDL-cholesterol; TG = triglycerides 
• may increase in some patients with previously low LDL-cholesterol and very high triglycerides 
1.6.1. The response to lipid-lowering drug therapy 
Several groups of drugs are available to treat hyperlipidaemia. They include the fibric 
acid derivatives, nicotinic acid compounds, fish oil, anion exchange resins such as 
cholestyramine and colestipol, probucol, the HMG-coA reducase inhibitors and neomycin 
(Thompson, 1990). The former three drug groups are predominantly triglyceride-lowering 
agents and the last four groups are cholesterol-lowering agents with various additional 
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properties. Fibrates and nicotinic acid are the two most effective types of triglyceride-
lowering drugs. They also raise HDL-cholesterol and are used to treat patients with high 
triglycerides or low HDL-cholesterol levels. p-hydroxy-P-methylglutaryl coenzyme A (HMG 
CoA) reductase inhibitors have been shown to be useful in patients with combined 
hyperlipidaemia who are unable to take nicotinic acid (Larsen, 1994). 
The effects of these different groups of lipid-lowering dmgs on the plasma lipid 
fractions are summarised in Table 1.5. 
1.6.1.1. The response to the fibric acid derivatives 
The fibrates are a family of drugs used to treat hyperlipidaemia which are relatively 
new in Hong Kong although they have been widely used in clinical trials and are well 
established in Westem countries. It has been shown that fibrates are effective in the therapy 
of combined hyperlipidaemia, especially when hypertriglyceridaemia predominates. Fibrates 
include clofibrate, etofylline clofibrate, fenofibrate, gemfibrozil, bezafibrate, ciprofibrate, 
etofibrate and becofibrate etc. (Thompson, 1990; Illingworth, 1993; Klosiewicz-Latoszek et 
al, 1991; Davignon, 1994). Fibric acid derivatives can reduce triglycerides, cholesterol and 
VLDL levels in plasma and they also raise plasma HDL-cholesterol. These effects have been 
shown by the all the fibrates. Nevertheless, there are important differences between the 
individual fibrates (Table 1.6). 
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Table 1.6 Comparative activity of five f!brates 
(Adapted from Blane, 1987) 
Clofibrate Bezafibrate Gemfibrozil Ciprofibrate Fenofibrate 
Daily dose (mg) 1,500-2,000 m 600-1,800 100-200 200-400 
Firstmarketed 1965 1978 1982 1985 1975 
Lipid-modifying 
effects (A %)* 
TC (IIAandII B) 8-29 11-28 2-16 20-22 16-40 
L D L - C ( I I A & I I B ) - 15-27 6-23 11-30 15-30 
HDL-C 0-8 0-41 13-25 6-25 0-22 
TG(IIBand IV) 20-60 26-68 35-60 30-76 29-71 
VLDL-TG - 30-67 40-60 37-42 40-70 
Plasmauric acid 0 0 ？ ？ 10-28 
(A %) 
LDL = low-density lipoprotein; HDL = high-density lipoprotein; VLDL-TG = very low-density lipoprotem-
triglyceride 
*o/o 二 percent reduction in cholesterol and uric acid 
Treatment with fibrates may also change the distribution of LDL subspecies with a 
shift away from a predominance of small dense LDL subspecies towards a predominance of 
large less dense and less atherogenic LDL subspecies (Illingworth, 1993). Fibric acid 
derivatives have been shown to reduce the blood lipid levels through the activation of 
lipoprotein lipase, suppression of free fatty acid release from adipose tissue, inhibition of 
hepatic triglyceride synthesis and increased secretion of cholesterol into bile. They raise 
HDL-cholesterol, especially the HDL3 subfraction, they inhibit synthesis and/or secretion of 
VLDL by the liver, and they influence the expression of certain genes involved in lipid 
metabolism, promoting the fractional clearance rate of triglyceride-rich lipoproteins, reducing 
de novo fatty acid synthesis in the liver by inhibition of acetyl-coenzyme A (coA) 
carboxylase, the rate-limiting enzyme in fatty acid biosynthesis and they are potent enhancers 
of mitochondrial and peroxisomal fatty acid beta-oxidation (Larsen, 1994; Davignon, 1994; 
Shepherd, 1994). Side effects are not common with fibrate and mainly consist of upper 
gastrointestinal upset, headache, fatigue, myalgia, loss of libido, increased frequency of 
gallstones and alopecia (Davignon, 1994). 
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Fibrates belong to a group of chemicals called peroxisome proliferators which also 
include fatty acids and certain herbicides. It has been known for many years that these 
compounds induce peroxisome proliferation in rodents resulting in hepatomegaly (Reddy et al 
1982; Lock et al 1989) and after prolonged administration possibly hepatocarcinogenesis 
(Reddy et al, 1980). Recent studies have demonstrated that a group of transcription factors 
called peroxisome proliferator activated receptors (PPARs) mediate the transcriptional 
activation process (Isseman et al, 1990; Dreyer et al, 1992). The PPARs are members of the 
superfamily of nuclear hormone receptors which regulate the expression of genes containing 
specific response elements, called peroxisome proliferator response elements (PPREs). 
Functional PPREs have been found in certain genes encoding enzymes involved in the 
peroxisomal p-oxidation pathway, such as acyl-coA oxidase (Marcus et al, 1993), in the 
cytochrome P450 4A6 gene (Muerhoff et al, 1992), in the 3-hydroxy-3-methylglutaryl-coA 
synthase gene (Gulick et al, 1994) and a regulatory sequence of the apolipoprotein A-I gene 
(Vu-Dac et al, 1994). Fibrates have been shown to induce apo A-II gene expression in 
hepatocytes ofrat and man by this mechanism (Berthou et al, 1995; Vu-Dac et al, 1995). The 
fibrates also decrease apo C-III transcription (Staels et al, 1995) and up-regulate lipoprotein 
lipase expression (Auwerx et al, 1996) so their mechanism of action is becoming more clearly 
understood although still not entirely predictable in individual patients. 
Gemfibrozil (5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid) is a homologue 
of clofibrate. Its mechanism of action is similar to that of other fibrates. It can reduce 
triglycerides to a greater extent than some of the other fibrates. Gemfibrozil has proved to be 
highly effective for lowering levels of plasma triglycerides and also for reducing the total 
cholesterol, VLDL-cholesterol and LDL-apolipoprotein B levels in some cases as well as 
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raising HDL-cholesterol levels in patients of non-Chinese origin (East, 1988). It decreased 
plasma lipid levels more than etofibrate and etofylline clofibrate in Type IIb patients in one 
study and in Type IV cases, gemfibrozil was significantly more potent in reducing the 
triglyceride levels than fenofibrate, etofibrate or etofylliine clofibrate (Klosiewicz-Latoszek et 
al, 1991). The VLDL triglyceride and cholesterol levels were significantly decreased during 
treatment with different fibrates but the greatest percentage fall was with gemfibrozil 
treatment (Klosiewicz-Latoszek et al, 1991). The formulation of gemfibrozil as a 900 mg 
once daily tablet preparation appears to be as effective as the conventional 600mg twice daily 
regimen in some studies including one involving Chinese non-insulin-dependent diabetic 
patients with dyslipidaemia (Ko et al, 1995). Both preparations of gemfibrozil were well 
tolerated in this study. It has been shown to reduce cardiovascular events in the Helsinki Heart 
Study (Frick et al，1987). 
Bezafibrate (2- [4- [2-(4-chlorobenzamido) ethyl] phenoxyl-2 methyl-propionic acid ) is 
another lipid-lowering fibric acid derivative. The mechanism is similar to that with 
gemfibrozil. Bezafibrate was shown to produce a marked decrease in elevated triglyceride 
levels, a raise in HDL-cholesterol levels and reductions in total cholesterol and LDL-
cholesterol levels. It also decreased elevated levels of lipoprotein(a), apolipoprotein B and 
fibrinogen. Bezafibrate is effective in most types of primary and secondary dyslipidaemia. 
Bezafibrate may be a good choice for patients who suffer non-insulin dependent diabetes 
mellitus and are likely to have increased fibrinogen levels. Bezafibrate also improved the 
serum lipid profile in diseases such as renal insufficiency or following cardiac surgery. 
Bezafibrate has now been shown to have a beneficial effect on retarding the atherosclerotic 
process and reducing the progression of coronary heart disease in young male post-infraction 
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patients in the Bezafibrate Coronary Atherosclerosis Intervention Trial, BECAIT, (Ericsson et 
al, 1996). Bezafibrate is as well tolerated as other fibrates. Few adverse events have been 
observed in clinical trials of bezafibrate. Cutaneous reactions and gastrointestinal symptoms 
are the most frequent side effects with loss of libido, headache and drowsiness reported less 
often. Rhabdomyolysis with worsening renal impairment are uncommon. Patients with 
diabetes mellitus or previous cardiac surgery have tolerated the drug well. The recommended 
dosage ofbezafibrate for dyslipidaemic patients is generally 400mg once daily as a sustained 
release tablet in conjunction with dietary management. Dosage reduction is required in 
patients with mild to moderate renal dysfunction depending on semm creatinine levels and it 
is contraindicated in the presence of severe renal failure (Goa, 1996). 
1.6.2. Detection ofhyperlipidaemia and benefits oftreatment 
Hyperlipidaemia has been shown to damage the cardiovascular system and cause 
many complications such as coronary heart disease, stroke and claudication. Hyperlipidaemia 
is most closely correlated with coronary heart disease (CHD). A high proportion of 
individuals dying from CHD would have had hypercholesterolaemia during life and thus be 
identifiable as being at higher risk. It has been proven that reduction of blood lipid is 
worthwhile to prevent the coronary heart disease. A reduction of CHD has been observed 
with reductions in total cholesterol along with decreases in LDL-cholesterol and increases in 
HDL-cholesteroL For every 1% decrease in semm total cholesterol, there is a 2.5% reduction 
in CHD risk (Holme, 1993) according to a recent meta-analysis of 19 primary and secondary 
prevention trials oflipid-lowering drugs or diet. 
It has been observed that there is strong positive association between serum 
cholesterol level and ischaemic heart disease mortality rates in different races. The prevalence 
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ofcoronary heart disease and mortality is about one-eight to one-quarter ofthe average figures 
for Caucasians among the ethnic Chinese in Hong Kong. The age-related increase in total 
cholesterol and LDL-cholesterol in both sexes is similar to findings in Caucasian population. 
However, little age-related change in HDL-cholesterol level was observed for men. With 
increasing age in women, the HDL-cholesterol fell. The relatively adverse lipid profile in 
men compared to women in Hong Kong is also comparable with studies in Caucasians. 
Subjects in the higher socioeconomic groups had higher total cholesterol in Hong Kong. 
Correlations between indices oflipid profile, glucose tolerance indices and obesity are similar 
to those found in previous studies of Caucasian populations. 
Drug treatment should be considered when dietary therapy is not sufficient if the total 
cholesterol level is persistently >6.5 mmol/1 in the higher risk category or those with existing 
cardiovascular disorder but the National Heart Foundation of Australia recommends a 
desirable level of less than 5.5 mmol/1 for adults. Coronary heart disease has been found to 
increase steeply in Caucasian populations above these values. Although it is possible that 
there may be a racial difference in the susceptibility to developing cardiovascular disease at 
particular lipid levels, intervention is recommended at similar cut-off points of the lipid 
profile for the Chinese population as in Caucasians. Previously, the lower prevalence of 
coronary heart disease among Hong Kong Chinese may have been related to the traditional 
Chinese low fat diet. However, the present dietary habits of Hong Kong Chinese may be 
increasing to a higher fat intake under the Western influence and general affluence of the 
Hong Kong people. The absolute benefit of intervention for individuals will depend on the 
incidence of coronary artery disease in the population. Cholesterol-lowering treatment has 
been shown to reduce the risk of coronary heart disease and produce angiographically 
detectable regression ofatherosclerosis. Furthermore, lipid-lowering therapy has an important 
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beneficial effect on the regulation of coronary arterial tone, favouring diminished 
vasoconstriction and improved vasodilatation in patients with symptomatic coronary 
atherosclerosis. The normalization of oxygen-derived free radical production is associated 
with the reduction in semm cholesterol. Lipid-lowering therapy can improve both epicardial 
and microvascular coronary endothelial responses. The more extended the period of lipid-
lowering therapy, the further the endothelium-dependent response retums toward normal 
levels (Treasure et al, 1995). It appears to be because oxidized LDL-cholesterol impairs 
endothelium-mediated relaxation and hypercholesterolaemia and atherosclerosis impair 
endothelium-mediated vasodilatation. The pathogenesis of myocardial ischaemia is thought 
to involve the loss of endothelium-mediated vasodilatation. 
1.6.3. The significance ofthe present studies 
The Hong Kong people of Chinese origin have attained lipid profiles similar to the 
populations of developed Western countries. In recent years, Hong Kong Chinese people 
have been faced with increasing coronary artery disease mortality. Therefore, an effort should 
be made to reduce the blood lipid levels in this population (Fong et al, 1994). 
The enormous economic growth and the extent of urbanization in recent decades has 
changed the Hong Kong people's lifestyle, so that the traditional Chinese culture and dietary 
habits are being affected and are becoming similar to those in affluent Westem countries. Up 
to now, there are no prospective data on lipid-lowering therapy in Hong Kong Chinese and 
data on apolipoprotein profiles in Chinese have been limited. The data from the WHO 
programme of Multinational Monitoring of Trends in cardiovascular disease observed that the 
relative contribution to coronary disease risk made by cholesterol differs between races. In 
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the United States and Europe data suggest that the ideal plasma cholesterol concentration is 
<5.2 mmol/L 
Because the response to many drugs has been found to be altered in various ethnic 
groups and elevated cholesterol and triglyceride levels are being detected with increasing 
frequency in patients in Hong Kong so that the number of patients in whom medication in 
indicated is rising likewise, we decided to commence clinical prospective studies to see how 
patients of Chinese origin in Hong Kong would respond to the fibrates. 
Firstly, we conducted a dose-response study of gemfibrozil in Chinese patients with 
hyperlipidaemia to determine the most effective dose of gemfibrozil for patients of Chinese 
origin. It is important to set up the dose-response relationship for Chinese patients and this 
should also be compared in different age groups, although the fibrate drugs are generally well 
tolerated with few severe side effects. Secondly, we performed another study to assess the 
efficacy and tolerability of a new formulation of gemfibrozil as a 900 mg tablet in the 
treatment ofhyperlipidaemia. Previously this was only available in a capsule formulation that 
had to be taken twice daily and may be difficult to swallow for some patients. A new tablet 
formulation containing 900 mg gemfibrozil had been produced and appeared to be effective 
with once daily dosing. This may lead to improved compliance and patient acceptability. We 
studied the effects ofthis new formulation on the detailed lipid profile of patients with mixed 
hyperlipidaemia and hypertriglyceridaemia. 
Lastly, we performed a study to assess the efficacy, tolerability and effects on 
glycaemia and coagulation factors of bezafibrate retard in the treatment of hyperlipidaemic 
patients in whom fibrate treatment appeared particularly indicated. Bezafibrate has been 
shown to improve glycaemic control in some groups of diabetic patients. 
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Chapter 2 Hyperlipidaemia: relationship to other diseases 
2.1. Atherosclerosis 
Atherosclerosis involves a combination of changes in the intima of arteries 
including the focal accumulation of lipids, fibrous tissue and other blood constituents, 
accompanied by changes in the media of the vessel wall. These features are due to the 
interaction between the metabolic and structural properties of the arterial wall, 
haemodynamic forces and components of the blood. The influence ofblood pressure and 
raised plasma lipids are two major modifiable factors for the occurrence of 
atherosclerosis and other determinants of atherosclerosis which cannot be altered are age 
and being ofthe male sex. An increased prevalence of atherosclerotic disorders has been 
reported in individuals with increased levels ofLDL apoB. 
From the pathological point of view, atherosclerotic lesions consist of fibrous 
plaques which are formed of a cap of smooth muscle cells and fibrous tissue covered by a 
layer of endothelium and a core of yellowish lipid material containing cholesterol esters. 
Hypercholesterolaemia or other factors can lead to clusters of monocytes becoming 
attached to the endothelial surface of arteries. These monocytes subsequently penetrate 
beneath the endothelium, engulf lipid and change to foam cells, that is to say 
macrophages containing large amounts of esterified cholesterol. The subendothelial 
collection of foam cells, seen by the naked eye, appears as fatty streaks. Hyperplasia of 
smooth muscle cells occurs with the eventual conversion of a fatty streak into a 
proliferative lesion. The fibrous cap may eventually rupture and expose the underlying 
macrophages and lipid deposits to the circulation. This results in adherence of platelets 
with mural thrombus formation and possible complete occlusion of the vessel. Atheroma 
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can be produced in a number of animal species by diet-induced hypercholesterolaemia 
providing supporting experimental evidence for the involvement of cholesterol in this 
process. The atheromatous lesions may gradually regress after withdrawal of the dietary 
stimulus and return ofthe plasma cholesterol to basal levels (Thompson, 1990; Feher and 
Richmond, 1995; van Berkel et al, 1994; Hamsten et al, 1994). 
2.2. Vascular Insufficiency Diseases 
As mentioned above, atherosclerosis can damage and block the blood vessels. 
Several organs are more often affected such as the heart, brain, lower limbs and 
sometimes the mesenteric arteries.. As the blood supply to the heart is affected, the heart 
will have a diminished oxygen and nutrition supply for myocardial cell metabolism. If 
this situation persists for a period of time the myocardial cell will be damaged and in 
clinical terms this will lead to coronary heart disease manifesting as angina or myocardial 
infarction (Austin et al, 1988) patients will complain of chest pain, dyspnoea and perhaps 
palpitation. A similar process can occur in the lower limbs or mesentery if the blood 
supply to these organs is affected and the patients will present with symptoms such as leg 
pain and claudication for leg ischaemia or abdominal pain, vomiting or passing blood per 
rectum for mesenteric ischaemia. 
Stroke is another disease related to atherosclerosis and dyslipidaemia. In some 
studies, stroke shows a correlation with high serum lipoprotein Lp(a) concentrations and 
low apolipoprotein A-I concentrations and other studies also show that altered 
LDL-cholesterol and HDL-cholesterol metabolism are involved in the pathogenesis of 
carotid stenosis. The elevation of LDL-cholesterol and reduction of HDL-cholesterol 
may increase the risk of atherothrombotic brain infarction. High levels of lipoprotein 
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Lp(a) are a genetically controlled condition in some patients with premature ischaemic 
cerebrovascular attacks (Woo et al，1991; Ono et al, 1991). Fortunately, in the three 
studies described in this thesis, there are less than five patients with a previous history of 
ischaemic heart disease. 
2.3. Hypertension 
Hypertension and dyslipidaemia frequently occur together. In our three studies, 
about 71% patients have a history ofhypertension. They were all under treatment mainly 
using calcium antagonists, angiotensin-converting enzyme inhibitors (ACEI) or alpha-
receptor blockers during the studies. As blood pressure is equal to cardiac output times 
peripheral resistance, anything that increases the cardiac output or the peripheral vascular 
resistance will increase the blood pressure. High blood lipids which may accumulate in 
the wall of the blood vessels to form atherosclerosis and eventually block the lumen of 
the vessels will lead to loss of the elasticity of vessel wall. This will increase the 
peripheral vascular resistance and lead to an increase in the blood pressure although the 
process may often occur in the reverse order. 
In addition, some of the antihypertensive drugs, such as beta-blockers and thiazide 
diuretics, can cause hyperlipidaemia. Diuretics increase the total cholesterol and 
triglycerides because of the greater secretion of VLDL, LDL-cholesterol and 
apolipoprotein B levels but they have a variable effect on HDL-cholesterol. Beta-
blockers include non-selective betap and beta2-adren0cept0r antagonists which often 
raise the triglycerides and reduce the HDL-cholesterol levels. Most of the beta-blockers 
raise triglycerides about 15% to 20% with reduction of HDL-cholesterol by 
Chapter 2 Hyperlipidaemia: relationship to other diseases 26 
approximately 10% but they usually do not change the concentration of the total 
cholesterol and LDL-cholesterol (Thompson, 1990; Oberman, 1992; Tomlinson, 1994). 
2.4. Diabetes mellitus 
In most developed countries, atherosclerosis is the major cause of death and 
disability in diabetes mellitus. Over three quarters of adult diabetics die from vascular 
disease affecting the coronary, cerebral or peripheral arteries. The overall increase in the 
risk for vascular disease in diabetics is about threefold but in the Framingham Heart 
Study this varied from a twofold increase for CHD in men to a more than eightfold 
increase for peripheral vascular disease and heart failure in women. Women with 
diabetes lose the protection against CHD enjoyed by their non-diabetic premenopausal 
counterparts. 
Part of the increase in risk in diabetes is due to an increased prevalence of the 
other risk factors. This is particularly so in non-insulin-dependent diabetes ^s[IDDM). 
The proportion of diabetics with NIDDM is greater in Asian populations, reaching 97% 
in the Chinese patients in Hong Kong. Hypertension is found in up to 50% of NIDDM 
patients and obesity, which appears as an independent risk factor for CHD in some 
studies, is present in up to 85% . Central, or more accurately visceral obesity, is linked 
with insulin resistance and hyperinsulinaemia in the metabolic syndrome, which can be 
present without overt diabetes. This is associated with the typical pattem of 
dyslipidaemia which occurs in over 60% ofNIDDM patients (Chan et al, 1996). 
Dyslipidaemia is common in diabetes mellitus, particularly non-insulin dependent 
diabetes mellitus G^IDDM) (Betteridge, 1994). There are about 38% patients of the 
patients in our three studies who have a history of NIDDM. Some of them are under 
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treatment by using metformin and glibenclamide and the others are on diet control. The 
patients with NIDDM classically have elevated levels of very low density lipoprotein 
(VLDL) particles and plasma triglyceride concentrations and often accompanied by 
reduced HDL-cholesterol. The total cholesterol and LDL-cholesterol concentrations may 
remain normal. Peripheral insulin resistance and compositional lipoprotein abnormality 
also occur in patients who have diabetes. Because of peripheral insulin resistance, the 
patients predestined to develop diabetes mellitus, who may have impaired glucose 
tolerance or mild elevation of fasting plasma glucose concentrations, frequently have 
increased plasma insulin levels. Peripheral insulin resistance is associated with increased 
hepatic synthesis of VLDL leading to hypertriglyceridaemia. The degree of 
hyperinsulinaemia and the VLDL triglyceride secretion rate usually have a direct 
relationship. The hypertriglyceridemia can be due to a defect in VLDL removal from the 
circulation or increased release of free fatty acids from peripheral tissues providing the 
liver with more substrates for hepatic triglyceride synthesis. The plasma triglyceride 
concentration changes with the hepatic triglyceride secretion rate until the concentration 
reaches about 5.56 mmol/1 (Oberman, 1992). 
Compositional lipoprotein abnormalities also occur in diabetic patients. There is 
an increased transfer oftriglyceride from VLDL to LDL and cholesteryl esters from HDL 
to VLDL and VLDL remnants (Oberman, 1992). Even in the absence of evident 
dyslipidaemia, dynamic alterations in lipoprotein composition may occur in these 
disorders. The elevation of VLDL and triglyceride levels of diabetic patients may be 
important risk factors for the development of vascular disease. This atherogenic lipid 
profile centering around hypertriglyceridaemia is also associated with abnormalities of 
the coagulation system, including raised levels of fibrinogen, factor VII and PAI-1 and 
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decreased levels oftPA. Platelet aggregability is also increased. This procoagulant state 
is not only found in diabetics but is a feature of the more general insulin resistance 
syndrome which usually includes elevation of triglycerides. Increased urinary albumin 
loss is associated with this atherogenic lipid profile in NIDDM and higher levels of 
plasma lipoprotein(a) may accompany micro- or macroalbuminuria. 
Table 2.1. Typical Pattern of Dyslipidaemia in Non-insulin Dependent Diabetes 
Mellitus. (Betteridge, 1994) 
Increased triglyceride, VLDL and IDL 
Postprandial lipaemia 
Decreased HDL2 - cholesterol 
Small dense LDL particles 
increased susceptibility to oxidation 
glycosylation ofLDL 
Apo AI decreased 
Apo B normal or increased 
On univariate analysis, elevated triglycerides are generally associated with an 
increased risk for CHD in epidemiological studies (Austin, 1989) especially in diabetic 
populations. Combined elevation of both triglycerides and cholesterol levels is 
particularly harmful in diabetics. The Paris Prospective Study showed that this pattem 
increased the CHD mortality threefold in diabetic men (Fontbonne et al, 1989). This 
pattem along with low HDL-cholesterol is also harmful in non-diabetics. The highest 
incidence of CHD in non-diabetic populations was seen in men with the combination of 
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elevated triglycerides and a high ratio oftotal or LDL-cholesterol to HDL-cholesterol in 
both the Prospective Cardiovascular Munster (PROCAM) study (Assmann and Schulte, 
1992) and the Helsinki Heart Study (Manninen et al, 1992). 
The American Diabetes Association recommends an aggressive approach to the 
treatment of dyslipidaemia in diabetes. Diet, exercise and careful glycaemic control are 
essential first line management in all diabetics and these should be vigorously reinforced 
in those with dyslipidaemia. Weight reduction will be particularly helpful in the obese. 
However these measures are often not sufficient to correct the lipid abnormalities and 
drug treatment should be considered iflipids remain in the high risk range (LDL-C > 4.2 
or TG > 4.5 mmol/l) in any diabetic or in the borderline range (LDL-C > 3.4 or TG > 2.3 
mmol/l) if HDL is low or there is another additional major CHD risk factor. If 
macrovascular disease is present the ADA recommends aiming for an LDL-cholesterol 
level < 2.6 mmol/1 (100 mg/dl) and triglyceride < 1.7 mmol/1 (150 mg/dl) (ADA 
Consensus Statement, 1993). 
Table 2.2. 
Risk categories by lipid levels in mmol/1 (mg/dl) in adult diabetic patients. 
^ TC LDL-C HDL-C TG 
m ^ 26.2 (240) 24.2(160) <0.9 (35) 24.5 (400) 
Borderline 5.2-6.2 3.4-4.2 - 2.3-4.5 
(200-240) (130-160) (200-400) 
Acceptable <5.2 (200) <3.4(130) <2.3(200) 
Adapted from American Diabetes Association Consensus Statement, 1993 
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In diabetics the full lipid profile including total cholesterol, HDL-cholesterol and 
triglycerides should always be measured. The LDL-cholesterol can then be calculated 
unless the triglycerides are very high. As the predominant abnormality is often raised 
triglycerides with low HDL-cholesterol, a fibrate drug, such as gemfibrozil, may be the 
best first line treatment (Betteridge, 1989). If LDL-cholesterol is particularly high, an 
HMG-CoA reductase inhibitor should be used initially. Nicotinic acid might appear to be 
useful for this pattem of dyslipidaemia but it tends to increase insulin resistance and is 
not recommended in diabetics. Bile acid sequestrates may increase triglyceride levels but 
they may be effectively combined with a fibrate. 
The increased cardiovascular risk in diabetes is a predominant cause of mortality 
and morbidity. Dyslipidaemia is one of the major contributing factors, but with careM 
assessment and vigorous management it may be possible to counteract this problem. 
2.5. Thyroid disorders 
Hypercholesterolemia is seen in patients with hypothyroidism. Patients with 
thyroid disease have abnormal LDL receptors which plays a major role in determining 
the cholesterol concentration. In hypothyroidism, there is a decreased rate of LDL 
catabolism caused by decreased synthesis and expression of the LDL receptor, and the 
plasma half-life of LDL is prolonged. The rate of apolipoprotein B syntheses and HDL 
metabolism may be influenced by thyroid hormone. The abnormalities in the 
concentration and metabolism of cholesterol are considered to be most typical for 
patients who have thyroid disease but changes may also occur in the concentration and 
metabolism of VLDL, and hence triglyceride. Hypothyroidism is associated with 
decreased LPL activity which consequently decreases clearance of VLDL and increases 
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blood triglycerides (Oberman, 1992). In our three studies, we have not found any patient 
with a thyroid function disorder. 
2.6 Liver disease 
The liver is the organ which probably has the most central role in lipoprotein 
metabolism. VLDL particles are synthesized in the liver, secreted into the bloodstream 
and converted to intermediate density lipoproteins (IDL) and LDL. The liver is 
quantitatively the most important organ for clearing LDL, containing approximately 75% 
of all LDL receptors in the body. Hepatic triglyceride lipase, localized in hepatic 
endothelial cells, plays a unique role in the conversion of IDL to LDL and the regulation 
of HDL subgroup concentrations. In addition, the liver is an important site of HDL 
synthesis. Because LCAT, the circulating enzyme solely responsible for all lipoprotein 
cholesteryl esterification, is synthesized only in the liver, cholesterol esterification in the 
HDL particle is also controlled indirectly by hepatic function (Oberman, 1992). 
Therefore, hepatic dysfunction may lead to numerous lipoprotein and lipid abnormalities. 
Acute hepatocellular disease is often associated with hypertriglyceridemia and 
decreased HDL-C levels. This may result from decreased hepatic triglyceride lipase 
(HTGL) activity, with subsequent accumulation of triglyceride-rich IDLs and VLDL 
remnants (Oberman, 1992). Cholestatic liver disease is often associated with 
hypercholesterolaemia. The plasma of such patients contains an abnormal lipoprotein 
called lipoprotein-x (LP-X) This lipoprotein appears as a bilamellar disk by electron 
microscopy and contains phospholipid, free cholesterol, apolipoprolein C and minor 
amounts of triglyceride. It may be responsible for the hypercholesterolaemia found in 
patients who have cholestasis (Oberman, 1992). 
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2.7. Pancreatitis 
Severe hypertriglyceridemia is associated with episodes of abdominal pain which 
may be due to pancreatitis. Acute pancreatitis is caused by hydrolysis of triglyceride 
within the pancreas by lipase with the result of releasing free fatty acids (FFAs) causing 
local damage to the gland. Chronic pancreatic insufficiency is seen in some patients who 
have had repeated attacks. Hypertriglycerdemia can be due to primary or secondary 
causes. When triglyceride levels exceed 30 mmol/l, recurrent episodes of pancreatitis 
with typical pain and hyperamylasemia can occur. Such patients usually also have an 
increase in VLDL and chylomicrons (Type I). When triglyceride concentrations exceed 
20 mmol/l. occasional spontaneous attacks of pancreatitis may occur (Oberman, 1992). 
However, the relationship between chylomicronaemia and pancreatitis may sometimes be 
altered by the disease itself. For example, triglyceride concentrations may appear normal 
in some patients who have pancreatitis in whom hypertriglyceridaemia provoked the 
attack, but because of the accompanying pain and nausea they were prevented from 
eating which allowed the triglyceride levels to return to normal. In the study of 
bezafibrate described later, one patient had suffered pancreatitis before. 
2.8. Renal disease 
2.8.1. Nephrotic syndrome 
Patients with the nephritic syndrome have increases in both plasma cholesterol 
and triglyceride levels which relate inversely to the blood albumin. This is because the 
proteinuria causes low blood albumin which stimulates the liver to produce more 
albumin which is accompanied by increased synthesis of apolipoprotein-B-containing 
lipoproteins and increased conversion of apolipoprotein-B containing remnants to LDL. 
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The LDL-C is increased but HDL-C is decreased accompanied by abnormalities in 
lipoprotein composition (Oberman, 1992; Warwick and Packard, 1993; Rayner et al, 
1990). The lipid abnormalities of the majority of patients are either 
hypercholesterolaemia, hypertriglyceridaemia or a mixed dyslipidaemia. The 
overproduction of lipoproteins returns to normal after recovery as indicated by kinetic 
studies. 
2.8.2. Chronic renal failure 
Patients with chronic renal failure often have significant lipid abnormalities. 
Hypertriglyceridaemia is found in 20% to 70% of dialyzed and undialyzed patients who 
have chronic renal failure This is the result of a combination of increased VLDL 
secretion and reduced rates of VLDL removal (Oberman, 1992). The main lipoprotein 
phenotype is hypertriglyceridaemia or Type IV. The defects in the lipolytic cascade arise 
from decreases in LPL and HTGL activities. The extent of the hypertriglyceridaemia is 
related to the postprandial insulin concentrations and also reflects the acquired insulin 
resistance of chronic renal failure (Oberman, 1992). The concentrations of VLDL and 
VLDL remnants are increased due to such defects. In chronic renal failure, HDL-C 
concentrations are decreased in quantity and are abnormal in composition. The ratio of 
LDL:HDL is increased in these patients who are known to have increased risk of 
developing vascular disease (Oberman, 1992). 
2.8.3. Renal transplant patients 
The elevation of lipids often correlates to the corticosteroid dose but in some 
studies, the prednisolone dose has been given on alternate days and the lipids have been 
reduced in some patients. Cyclosporin A treatment will also increase lipid levels. 
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Chapter 3. Patients and methods in the lipid studies 
3.1 Characteristics ofpatients with hypertriglyceridaemia in Hong Kong 
A group of the patients who took part in some of the treatment interventions 
described later were studied to document the clinical features and pattem of 
dyslipidaemia in Chinese patients attending the lipid clinic with moderate to severe 
hypertriglyceridaemia (TG > 3 mmol/l). Previous studies in Sweden and other western 
countries (Asplund-Carlson, 1994; Thompson, 1988; Shaper et al, 1991) have shown that 
hypertriglyceridaemia is associated with: 
* central obesity, hypertension, low physical activity, heavy smoking and high alcohol 
intake 
* raised glucose, urate, gamma GT, apolipoprotein B and PAI-1 
* reduced HDL-C and apolipoprotein AI 
Patients were recruited from those attending the lipid clinic with fasting TG > 3.0 
mmol/1 on 2 occasions. The sample may have been biased because many patients were 
discovered by screening patients attending with other CHD risk factors, particularly 
hypertension. Patients attending the diabetic clinic with NIDDM also have regular lipid 
screening, but they are less commonly referred to the lipid clinic than those from the 
hypertension clinic. 
Poorly controlled diabetics were excluded and antihypertensive treatment was 
modified to reduce effects on lipids so the main treatments used were calcium 
antagonists, angiotensin-converting enzyme (ACEI) inhibitors or alpha�receptor 
blockers. 
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Data for 35 patients with hypertriglyceridaemia are shown in Tables 3.1 and 3.2. 
Comparing male and female patients (Table 3.1), the males tended to be younger and 
heavier with greater BMI and waist circumference. A greater proportion of the female 
patients had hypertension +/- NIDDM. 
Table 3.1. Comparison ofmale and female patients with hypertriglyceridaemia 
Males Females 
n U ^ 
Age (yrs) 43.1 士 2.7 60.6 土 2.3 
Weight (kg) 761 土 2.9 60.6 士 2.3 
BMI (kg^m2) 27.9±0.9 25.6士0.8 
Waist: hips 0.92 士 0.01 0.88 土 0.02 
HT 8 (57%) 18 (86%) 
HT + NIDDM 2 (14%) 5 (24%) 
The plasma lipids, glucose, urate and gamma GT results are shown in Table 3.2. 
Gamma GT levels were raised in 1 female (aged 65) & 3 males ( 35, 40 & 45 yrs). This 
was possibly related to alcohol in the young male patients. 
Triglyceride levels were > 10 mmol /1 in 5 patients and had been this high before 
in many of the others but only 1 patient (male) had a history of pancreatitis. Most 
patients had elevated total cholesterol and only 4 had levels < 5.2 mmol /1. 
Comparing the Chinese male patients in Hong Kong with those described in the 
study in Sweden (Asplund-Carlson, 1994), the Chinese patients were less heavy and had 
lower waist circumference but had a similar BMI to the Swedish patients. The 
cholesterol and triglyceride levels were higher in the group studied in Hong Kong but 
gamma GT levels were higher in the Swedish group. 
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Table 3.2. Plasma lipids, glucose, urate and gamma GT in 35 patients with 
hypertriglyceridaemia 
mmoVl ~ M e a n ± SE ( r a n g e ) ~ normal range 
rc 6.6d:1.0 (2.2 - 36.0) < ^ 
TC 7.0士0.3(4.7-11.7) <5.2 
HDL - C 1.02 士 0.08 (0.5 - 2.7) M > 1.0 ； F > 1.2 
Glucose 5.5 土 0 1 (4.4 - 7.8) 3.9 - 6 1 
Urate 0.36 土 0.01 (0.23 - 0.50) 014 - 0.37 
Gamma GT 38.2 ± 10.6 (<30 - 244) M < 100 ； F < 84 
(U/1)  
Table 3.3. 
Comparison of male patients with hypertriglyceridaemia in Hong Kong and 
Sweden 
HK Chinese Sweden 
^ “ I i ^ 
Age (yrs) 431 士 2.7 44.9 士 3.8 
Weight (kg) 76.1 土 2.9 89.1 土 14.1 
BMI (kg^m2) 27.9 士 0.9 27.8 士 3.8 
Waist: hips (ratio) 0.92 土 0.01 1.00 土 0.06 
TG (mmoVl) 6.6 土 1.0 3.8 ±1.7 
TC (mmoVI) 7.0士0.3 6.6±1.2 
Gamma GT (U/I) 38 ±11 122 土 10 
Urate (mmoVl) 0.36±0.01 0.37土0.56 
These results indicate that hypertriglyceridaemia is associated with treated 
hypertension in Hong Kong Chinese patients, particularly in older females. Alcohol 
excess may contribute to raised triglyceride levels in some younger males but this 
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appears less common than in Western countries such as Sweden. Pancreatitis is rare in 
these patients with hypertriglyceridaemia even when triglyceride levels are greater than 
10 mmol/1. 
Most patients show the pattern of familial combined hyperlipidaemia (FCH). 
Limited family studies in these patients and their relatives support this. Also most of 
these patients show insulin resistance which has been demonstrated in other studies using 
a short insulin tolerance test. This may be a primary problem in these patients or it may 
be secondary to hypertension or its treatment or to the dyslipidaemia or to obesity. 
3.2. Clinical and laboratory methods to measure the response to drug treatment 
In the three studies described in subsequent Chapters we have used two methods 
to asses the response to the lipid-lowering drugs. One involves clinical assessment and 
the other involves laboratory methods. 
3.2.1. Clinical methods to assess the response to drug treatment. 
The history was taken to help classify the hyperlipidaemia, to observe any 
complication and to detect any side effect from drug treatment. The blood pressure, body 
weight, hip and waist circumference were measured every four weeks to observe any 
alteration during active drug treatment and blood samples were taken for laboratory assay 
to measure the plasma lipid levels during the study. 
3.2.1.1.History 
a) Present history: 
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We asked the patients regarding their compliance and any symptoms that may be 
caused by the hyperlipidaemia or the complication ofhyperlipidaemia. Any alteration of 
these symptoms was observed during the active treatment periods. Fortunately, there 
were only two patients in our three studies suffering coronary heart diseases but they did 
not have any vascular insufficiency symptoms during the studies. 
b) Social history 
We initially asked about the occupation, marital status, age and sex of their 
children and dietary history, alcohol intake, current and past smoking habit, amount of 
exercise taken and current drug history. Dietary changes and use of other drugs may 
affect the response to treatment and interfere with the interpretation of the results of 
response to the dmgs being tested. 
c) Side effect questionnaire 
Side effects including general health questions and specific questions related to 
muscle symptoms and to any disturbance of sleep were elicited by a side effect 
questionnaire given at each visit. 
3.2.1.2. Physical examination 
A full physical examination was performed by Prof. B. Tomlinson during 
screening of the patients. It included looking for the signs of hyperlipidaemia, 
examination of the cardiovascular system, abdomen and endocrine status. The external 
signs of hyperlipidaemia such as comeal arcus, xanthelasmata or xanthomata were 
particularly noted during the physical examination. Other signs were also sought like 
aortic murmur, diminished or absent pulses in the lower extremities and carotid bruits. In 
the examination of the abdomen, the size of the liver and spleen was assessed. The 
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endocrine status was also considered. During the active treatment periods, the above 
signs were observed for improvement although it was not thought likely that there would 
be much change in these features during the short duration of the studies. 
3.2.1.3. Clinical measurement 
Blood pressure, body weight, height, hip and waist were measured during drug 
therapy. Urine was tested for protein, glucose and blood during the studies to detect any 
damage to the kidneys which may have been drug related. During the studies, all the 
blood pressures and heart rates were measured by using the Critikon Dinamap, an 
automatic blood pressure machine. Body weight and height were measured by using a 
2 
Seca model 713 and the body mass index (BMI) was calculated as weight / height (kg / 
m^). A measuring tape was used to measure the hip and waist circumference in 
centimeters. The urine was tested by using Combure 9-test, one of the dipstick reagents. 
Blood was taken by using disposable syringes and sent to the chemical pathology 
laboratory for lipid analysis and other tests. 
3.3. The laboratory methods to measure the lipid response to drug treatment 
Fasting blood was taken for assessment of the standard plasma lipid profile, 
extended lipid profile, safety tests and coagulation studies. During active treatment 
periods, the standard plasma lipid profile and safety tests were done every four weeks 
and the extended lipid profile and coagulation tests were performed only at the beginning 
and the end of the studies. The standard plasma lipid profile included total cholesterol, 
triglycerides, HDL-cholesterol and LDL-cholesterol. These measurements were done by 
the routine chemical pathology laboratory as for normal clinical patient management. 
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The safety tests consisted of liver function tests including plasma alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl 
transferase (gamma-GT), plasma creatine kinase (CK), renal function tests and complete 
blood picture. These tests were also done by the routine chemical pathology or 
haematology laboratories 
Total cholesterol and triglyceride levels were measured enzymatically in plasma 
with commercial reagents (Dimension, Du Pont Instrument Company, Wilmington, 
Delaware). HDL-cholesterol levels were measured by the use of the same enzymatic 
assay used to measure total cholesterol, after precipitation of apolipoproteinB containing 
lipoproteins with dextran sulfate and magnesium chloride. The intra-assay coefficient of 
variation (CV) was less than 5% and the interassay CV was less than 8%. 
Haemoglobin Alc was measured using an automated ion-exchange 
chromatographic method (Bio-Rad Laboratory, Hercules, California). Fibrinogen levels 
were measured using a nephelometric method (ACL, instrumentation Laboratory Inc., 
Lexington Massachusetts). 
The extended lipid profile consisted of apolipoprotein A-I, apolipoprotein B and 
lipoprotein (a) [Lp(a)]. The coagulation studies consisted of fibrinogen levels. It was 
intended to measure Factor VIIc and PAI-1 but the assays were not available during the 
course of the studies. 
3.3.1. The methodology for the extended lipid profile 
The whole fresh blood was centrifuged at 3,500 revs/min cycles for 10 minutes 
using an Heraeus Christ centrifuge. Afterwards, the serum was kept at -70°C until the 
tests were performed. The serum apolipoproteinAI and apolipoproteinB were tested by 
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rate immunonephelometry using a Beckman protein analyzer apparatus (Beckman 
Instruments, Brea, California) which was composed of an Array 360 system, a control 
computer and a printer. The Array 360 system is the main apparatus which includes two 
chambers for the anti-lipoprotein and lipoprotein reaction to take place. The right hand 
side is a reagent wheel in which can be placed up to twenty reagents at the same time and 
the left hand side is another place for putting samples. There are two pipette-like tubes at 
each side of the apparatus. Their function is to dilute and mix the samples and then put 
the sample and the reagents into the central chamber for the reaction to take place. The 
apolipoproteinAI anti-lipoprotein and apolipoproteinB anti-lipoprotein were placed 
respectively at no.l2 and no.l3 of the right side reagent wheel. The sera to be analyzed 
for apolipoproteinAI and apolipoproteinB content were put at the left side. The serum 
was diluted 36 times before the reaction with anti-lipoprotein. The result ofthe reaction 
is relayed to the computer by the Array 360 system. The result can be obtained by using 
a sample programme on the computer. Afterwards, the result is printed out by the printer. 
Before testing the apolipoprotein Al and apolipoprotein B, it is necessary to wash the 
machine by using a primer and then to calibrate the apparatus with apolipoprotein AI and 
apolipoprotein B calibrator and control samples to get a standard value for reference and 
assess the accuracy of the apparatus before the test was commenced. Intra-assay and 
interassay CVs for the apolipoprotein measurements were both less than 9%. 
3.3.2. Statistical Analysis 
Statistical Analysis was performed with Quattro Pro software for Windows, 
version 5.0, Borland International, 1993 and Sigmastat, Version 1.0, Jandel Scientific, 
1994. Result were expressed as means and standard deviations (mean 士 SD), or standard 
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error of mean (SEM). Differences between repeated measures were evaluated by one 
way analysis of variance (ANOVA) followed by pairwise multiple comparisons if 
statistical significance was found on the ANOVA. If the data failed the initial test for 
normality, an ANOVA on ranks was performed using the Kruskal-Wallis one way 
Analysis of Variance on Ranks followed by an all pairwise multiple comparison 
procedure (Dunn's Method) if statistical significance was obtained. Differences between 
two sets ofdata were evaluated by t-test or by the non-parametric Wilcoxon Signed Rank 
Test ifthe data failed the test for normality. 
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Chapter 4. Gemfibrozil dose-response study 
4.1. Dose-response study ofgemfibrozil in Chinese patients with combined 
hyperlipidaemia 
4.1.1. Introduction 
Different ethnic groups may show varying responses to many drugs. However, 
most new drugs and many well-established drugs have only been studied systematically 
in one or two ethnic groups and dosage recommendations are applied on a worldwide 
basis without adequate data being available for other ethnic groups. The basic dose-
response studies have often not been done in many ethnic groups, particularly in patients 
of Chinese origin. In Hong Kong, elevated cholesterol and triglyceride levels are being 
detected with increasing frequency. Medication may be required in many ofthe patients. 
Many of the affected patients are elderly. Their metabolism and elimination of drugs is 
often impaired because of liver and renal disease. Also, because of multiple drug 
treatments, drug interactions are more common in this age group. 
Gemfibrozil, one of the fibrate group of drugs, is generally well tolerated with 
few severe side effects. Nevertheless, it is important to established the dose-response 
relationship for Chinese patients and, ideally, to compare this in different age groups. 
The advantages of gemfibrozil are that it not only lowers triglycerides and LDL-
cholesterol levels but it also increases HDL-cholesterol and may reduce lipoprotein (a) 
levels. It is generally used in a fixed dose of 600 mg twice daily because that dose was 
found to reduce cardiovascular events in the Helsinki Heart Study (Frick et al, 1987). 
There are relatively few studies looking at the dose response relationship with 
gemfibrozil (Todd and Ward, 1988) 
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This study was undertaken to investigate the effects of the standard dose range of 
gemfibrozil on the detailed lipid profile of Chinese subjects with hyperlipidaemia and to 
determine the tolerability of the different doses. 
4.1.2. Patients 
A total of 21 patients were recruited with either elevated total cholesterol (>6.5 
mmol/1) due to elevation of LDL-cholesterol along with moderately elevated 
triglycerides (>2.5 mmol/1) or with marked elevation of triglycerides (>5 mmol/1) with 
normal cholesterol. The majority of patients had combined hyperlipidaemia with 
predominant elevation of triglycerides. The nature and purpose of the study were 
explained to the recruited patients and written consent was obtained from them. The 21 
Chinese patients included 15 females and 6 males. The mean age of these patients was 57 
years, range from 34 years to 73 years. The patients' details are shown in Table 4.1. 
There were no contraindications to the trial drug or the procedures involved. 
Any previous lipid lowering therapy was stopped for at least 8 weeks before 
starting the active treatment phase of the trial. From this group of patients, 12 had 
hypertension treated mainly with calcium antagonists and 4 had well-controlled NIDDM 
but those taking drugs with known interaction with gemfibrozil were excluded. Patients 
with ischaemic events within the previous 6 months, such as myocardial infarction and 
cerebrovascular disease, those with any other serious illness which might interfere with 
the conduct of the trail and those with initial impairment of liver function tests were 
excluded from the study. The active treatment was commenced if the lipid profile was 
within the range defined above. The treatment was given in escalating doses with 
gemfibrozil 300 mg bd for 4 weeks, gemfibrozil 300 mg tds for the next 4 weeks and 
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gemfibrozil 600 mg bd for the third period of 4 weeks. The treatment was discontinued 
in 4 patients before completing the study because of intolerance of higher doses due to 
abdominal discomfort. 
4.1.3. Results 
The serum lipid levels during the study are shown in Table 4.2. The only 
significant changes by ANOVA were in triglyceride levels. As the baseline triglyceride 
levels failed the test for normality ofdistribution the analysis was performed by Kmskal-
Wallis one way analysis of variance on ranks followed by an all pairwise multiple 
comparison procedure (Dunn's Method). There was a marked fall in triglyceride levels 
from 9.94i2.86 to 2.80±0.30 mmol/1 (p<0.01) with 300 mg bd and small further 
reductions to 2.38士0.31 and 1.99i0.23 mmol/1 with the higher doses. This represents 
mean reductions of71%, 76% and 79%. Total cholesterol was reduced from 7.16i+0.43 
mmol/l maximally with 300 mg tds dose (6.08士0.31 mmol/1, p<0.01 by t test but not by 
ANOVA) and the maximum rise in HDL-cholesterol was from 0.98± 0.06 to 1.11± 0.07 
mmol/1 with the 300 mg bd dose (p<0.01 by t test). The apolipoprotein AI levels tended 
to fall and apolipoprotein B tended to rise but the changes were not significant (Table 
4.3). Lipoprotein Lp-(a) showed wide variations during the study with a tendency to rise 
(Table 4.3). 
No elevation of liver enzymes or plasma creatine kinase was detected during the 
study and fasting plasma glucose levels did not change (Table 4.4). The sitting and 
standing blood pressure tended to fall during the course of the study. The side effects 
reported by the patients during the course of the study are listed in Table 4.5. Two 
patients withdrew whilst taking 300 mg tds and a further one whilst taking 600 mg bd 
due to abdominal discomfort. 
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Table 4.1. Patient details for the gemfibrozil dose-titration study 
Subject S e x ~ A g e Height Weight~~m\ HT DM Additional 
number (m) (kg) (kg/m.m) treatment  
201 F 63 1.57 56.0 22.9 Y N IND1 tab od 
202 F 65 1.46 48.4 22.9 Y N NR 20 bd GEL 1 tab prn 
203 F 73 1.58 61.2 24.5 Y N NR 20 bd 
204 F 73 1.59 46.6 18.4 N N DPY75tds 
205 F 44 1.51 63.1 27.9 Y N IND2.5od EN 40 od 
206 F 54 1.53 61.0 26.1 Y Y GB5od MTP100 odNR20 bd 
207 F 65 1.53 65.0 27.8 N Y VER 40 bd ISD 5 tds 
208 F 60 1.52 56.7 24.7 Y N NR 20 bd 
209 F 66 1.58 64.0 25.8 N N EN 20 od FRU 20 od 
211 M 38 1.64 72.8 27.1 N N 
212 M 45 1.72 75.2 25.4 N N 
213 F 46 1.57 68.8 28.1 Y N AT 50 od DX 2 od 
214 F 61 1.46 44.6 20.9 Y Y GB 108/4 DX 2 od MDP 500 bd 
215 F 62 1.48 44.4 20.3 N N RAN 150 bd 
216 M 34 1.64 65.2 24.4 N Y MET 500 bd GB 2.5 od 
217 M 50 1.74 78.0 25.8 N N PRX10prn 
218 F 66 1.45 43.6 20.7 N N 
219 F 75 1.52 58.5 25.3 Y N EN5bd 
220 M 43 1.53 79.3 33.9 Y N NR40bd 
221 F 59 1.44 81.8 39.4 Y N AT100 odNR20 bd 
222 M 47 1.60 65.8 25.7 Y N AT 50 od ALP 300 od 
N M/F 21 21 21 21 12 4 
MEAN 6/15 56.62 1.55 61.90 25.61 
SD 12.02 0.08 11.78 4.60 
SEM 2.62 0.02 2.57 1.00 
Drug abbreviation: 
ALP = Allopurinol ISD 二 Isordil 
AT = Atenolol MDP = Melthyl dopa 
DPY = Dipyridamole MET = Metformin 
DX = Doxazosin MTP 二 Metoprolol 
EN 二 Enalapril NR = Nifedipine retard 
FRU = Frusemide PRX 二 Piroxicam (Feldene) 
GB = Glibenclamide RAN 二 Ranitidine 
GEL = Gelusil VER 二 Verapamil, (Isoptin) 
ES[D 二 Indapamide, ONfatrilix) 
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Table 4.2 Plasma lipid levels during the gemfibrozil dose-titration study 
Total cholesterol Triglycerides 
Subject baseline 4weeks 8weeks 12weeks Sufc>ject# baseline 4weeks 8weeks 12weeks 
201 7 5 6.5 6.6 6.4 201 12.37 2.86 2.63 2.38 
202 6.5 7.5 7.9 8.6 202 5.43 1.71 1.25 1.26 
203 6.7 6.4 5.5 7.2 203 8.57 2.64 1.66 0.87 
204 5 9 5.1 5.3 5.3 204 3.83 2.22 1.44 1.19 
205 6.0 5.3 5.7 5.2 205 9.39 1.68 1.32 1.19 
207 6 3 5.3 5.4 4.2 207 2.16 5.48 3.05 2.63 
208 7 5 7.4 7.7 8.4 208 6.70 2.73 1.88 1.03 
209 102 6.0 6.8 8.0 209 11.79 3.32 2.40 2.99 
211 7 7 9.1 8.3 9.6 211 3.52 0.98 0.84 0.81 
213 7 3 5.8 5.9 6.1 213 12.69 2.58 4.77 2.97 
214 7 0 7.1 6.2 6.1 214 11.6 3.37 3.31 2.63 
215 8.2 7.5 215 5.50 1.38 
216 12.7 6.3 6.2 216 61.0 5.00 4.68 
217 6 2 5.2 5.6 5.8 217 12.87 4.40 4.16 2.69 
218 7.5 6.8 218 3.01 1.08 
219 7 2 6 2 5 2 5.9 219 6.79 3.33 1.39 2.71 
220 6 4 7.0 7.2 6.1 220 3.18 4.56 2.97 3.57 
221 5.6 4.2 4.6 4.5 221 2.12 1.46 1.18 1.39 
222 3.6 3.4 3.3 3.7 222 6.4 2.37 1.57 1.6 
N 19 19 17 16 N 19 19 17 16 
MEAN 7.16 6.22 6.08 6.32 MEAN 9.94 2.80* 2.38*t 1-99* 
SD 1.87 1.31 1.26 1.66 SD 12.92 1.33 1.26 0.91 
SEM 0.43 0.30 0.31 0.42 SEM 2.96 0.30 0.31 0.23 
* p <0.05 compared to baseline; t P <0.05 compared to 4 weeks 
High density lipoprotein cholesterol Low density lipoprotein cholesterol 
Subject# baseline 4weeks 8weeks 12weeks Subject# baseline 4weeks 8weeks 12weeks 
201 0.78 0.96 1.15 1.04 201 4.2 4.3 4.3 
202 1.14 1.23 1.22 1.15 202 5.5 6.1 6.9 
203 0.91 1.19 1.17 0.82 203 4.0 3.6 5.2 
204 0.87 0.86 0.95 1.56 204 3.3 3.2 3.7 3.9 
205 0.93 1.14 1.13 1.22 205 3.4 4.0 3.4 
207 1.13 0.72 0.90 0.90 207 4.2 3.1 2.1 
208 0 92 1.18 1.03 1.06 208 5.0 5.8 6.9 
209 0.76 1.14 1.29 1.3 209 3.4 4.4 5.3 
211 0.89 1.02 1.09 1.18 211 7.6 6.8 8.1 
213 1.44 1.12 1.17 1.13 213 3.5 3.6 
214 0.73 0.94 0.69 0.79 214 4.6 4.0 4.1 
215 0.95 1.30 215 5.6 
216 0.82 1.16 1.07 216 
217 0.79 0.63 0.71 0.71 217 2.6 3 3.9 
218 1.79 1.91 218 4.4 
219 1.04 1.25 1.32 1.31 219 3.4 3.2 3.4 
220 1.16 1.53 1.25 1.22 220 3.8 4.6 3.7 
221 1.01 0.97 0.90 0.89 221 3.6 2.6 3.2 3 
222 0.59 0.86 0.83 0.85 222 1.5 1.8 2.1 
N 19 19 17 16 N 4 16 15 16 
MEAN 0.98 1.11 1.05 1.07 MEAN 3.73 4.03 4.11 4.37 
SD 0.27 0.29 0.19 0.23 SD 0.38 1.45 1.31 1.71 
SEM 0.06 0.07 0.05 0.06 SEM 丨 0.19 0.36 0.34 0.43 
no significant change on ANOVA 
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Table 4.3 
Plasma apo AI, apo B and Lp(a) levels during the gemfibrozil dose-titration study 
apo Al apo B 
Subject#basenne 4weeks 8weeks 12weeks Subject#baseline 4weeks 8weeks 12weeks 
201 119 123 137 131 201 163 185 191 184 
202 174 144 149 139 202 157 210 228 247 
203 150 155 151 165 203 141 165 144 184 
204 130 118 126 117 204 129 148 168 170 
205 149 128 132 130 205 143 146 147 129 
207 145 137 138 142 207 170 145 148 141 
208 144 150 137 138 208 181 208 220 248 
209 108 143 142 146 209 90 84 110 130 
211 119 110 119 126 211 215 245 232 260 
213 152 151 156 149 213 132 157 166 165 
214 121 121 109 112 214 162 201 185 193 
216 115 128 139 216 106 171 
217 113 116 111 109 217 106 152 164 174 
218 220 183 176 218 195 194 193 
219 136 153 150 163 219 136 139 126 139 
220 142 200 153 156 220 182 217 228 202 
221 135 130 119 116 221 163 126 138 131 
222 116 129 122 132 222 67 94 90 95 
Count 18 18 18 16 Count 17 18 18 16 
Mean 138.22 139.94 137.00 135.69 Mean 148.94 162.33 169.39 174.50 
SD 26.80 23.28 17.42 17.38 SD 37.64 44.69 41.28 47.61 
SEM 6.32 5.49 4.10 4.10 SEM 8.87 10.53 9.73 11.22 
Lp(a) 
Subject # baseline 4weeks 8weeks 12weeks 
201 32 219 206 156 
202 96 351 385 408 
203 127 276 233 366 
204 178 631 541 638 
205 43 277 204 322 
207 120 100 138 110 
208 282 320 457 734 
209 102 90 91 120 
211 39 111 101 123 
213 17 46 27 58 
214 182 392 393 415 
216 116 111 176 
217 15 21 20 39 
218 410 546 321 
219 91 111 122 186 
220 233 198 176 113 
221 185 158 155 153 
222 25 64 53 114 
Count 18 18 18 16 
Mean 127.39 223.44 211.06 253.44 
SD 104.67 172.11 150.71 208.02 
SEM 24.67 40.57 35.52 49.03 
no significant change on ANOVA 
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Table 4.4 Liver function tests, (alkaline phosphatase{Alk Phos}�alanine 
aminotransferase{ALT}), creatine kinase (CK) and glucose levels during the 
gemfibrozil dose-titration study 
Alk Phos ALT 
Subject# baseline 4weeks 8weeks 12weeks Subject# baseline 4weeks 8weeks 12weeks 
201 81 78 91 86 201 1 1 32 24 
202 91 80 82 77 202 1 1 26 38 
203 138 122 131 153 203 29 17 91 44 
204 96 87 94 89 204 26 30 33 40 
205 53 47 49 43 205 20 9 32 28 
207 104 94 90 127 207 71 69 80 76 
208 105 103 101 120 208 26 31 30 28 
209 84 78 77 209 42 42 38 
211 59 73 58 61 211 34 36 40 50 
213 30 35 38 44 213 42 59 70 
214 80 70 82 94 214 45 36 40 46 
215 79 78 215 37 39 
216 148 137 134 216 146 102 
217 103 87 92 86 217 45 49 58 61 
218 106 133 101 218 29 35 42 
219 83 99 94 107 219 25 28 27 28 
220 74 68 62 63 220 53 36 38 34 
221 146 125 114 153 221 43 32 46 58 
222 64 55 60 222 30 31 30 
N 17 19 18 16 N 15 19 18 16 
MEAN 92 71 87.58 85.89 90.00 MEAN 32.33 37.32 47.17 43.31 
SD 31 72 27.51 26.41 34.33 SD 18.23 30.84 22.46 15.85 
SEM 7.69 6.31 6.23 8.58 SEM 4.71 7.08 5.29 3.96 
(^l^ Glucose 
Subiect# baseline 4weeks 8weeks 12weeks Subject# baseline 4weeks 8weeks 12weeks 
201 71 59 51 114 201 5.4 5.2 5.3 5.2 
202 60 57 54 129 202 6.4 6.6 6.3 6.7 
203 91 99 138 151 203 5.4 5.3 6 5.7 
204 86 45 50 204 11.3 4.6 6.1 9.8 
205 67 74 58 68 205 5.7 5.4 5.6 4.6 
207 32 72 84 85 207 5 6.4 6.1 6.4 
208 91 92 117 180 208 5.2 5.2 5.5 5.1 
209 125 68 154 100 209 5.2 5.4 5.4 5.9 
211 152 159 131 188 211 5.2 5 5.1 5.2 
213 51 53 56 58 213 6.3 6.6 7 6.7 
214 43 39 33 38 214 8.1 9.1 8.1 6.4 
215 63 68 215 5.2 5.1 
216 158 168 133 216 9.5 7.8 9.4 
217 241 149 209 163 217 5.3 5.4 5.6 5.6 
218 115 101 108 218 5.1 5.7 5 
219 70 92 218 131 219 5.5 5 5.3 5 
220 205 164 215 138 220 5.8 6.3 5.6 6.6 
221 53 52 67 58 221 6.9 6.8 7.6 7.8 
222 114 99 119 222 4.8 4.8 5.2 5.1 
N 17 19 18 16 N 19 19 18 16 
MEAN 99.29 92.95 109.44 110.63 MEAN 6.17 5.88 6.12 6.11 
SD 59.30 40.45 60.03 47.49 SD 1.71 1.14 1.19 1.30 
SEM 14.38 9.28 14.15 11.87 SEM 0.39 0.26 0.28 0.32 
no significant change on ANOVA 
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Table 4.5. 
Side effects reported by the patients during the gemfibrozil dose-titration study 
n=22 n=20 n=19 n=17 
headache 8 7 5 5 
dizziness 3 4 4 4 
faintness 0 0 1 0 
fatigue 6 8 9 8 
sleepiness 5 8 9 6 
flushing 1 1 1 1 
cold fingers or toes 1 0 0 1 
swelling of feet or ankles 3 1 2 0 
abnormal weight gain 0 0 1 0 
rapid heartbeat 3 1 3 1 
slow heartbeat 0 0 0 0 
shortness ofbreath 3 5 6 1 
cough 2 6 7 6 
sputum 7 10 8 8 
nausea / vomiting 0 1 0 0 
heartbum 3 5 8 4 
abdominal pain 1 0 1 (1) 
constipation 3 3 5 5 
diarrhoea 1 0 2 0 
skinrash 4 4 3 2 
lose of taste 2 1 2 6 
hair loss 8 6 6 6 
dry eyes 4 2 5 4 
dry mouth 5 10 9 4 
difficulty in remembering things 14 12 12 11 
inability to concentrate 6 3 5 2 
abnormal moodswing 6 5 3 5 
depressed 7 5 2 3 
unable to fall asleep 7 4 4 3 
numbness or tingling in hands/feet 13 15 7 7 
nightmares 6 2 2 5 
waking up during night 10 9 8 8 
increased frequency of urination 2 4 4 2 
impotence 0 0 0 0 
decrease libido 12 11 10 9 
muscle cramp 5 4 3 2 
stiffness in muscle 5 5 2 2 
difficulty walking 1 0 0 0 
Drug withdrawal 0 2 1 2 
Total no. of side effects ^ ^ i ^ ^ 
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4.1.4. Discussion 
This study showed that gemfibrozil has a good effect in controlling 
hypertriglyceridaemia but not hypercholesterolaemia. The dose of 300 mg bd appeared 
especially cost-effective as it produced almost as much effect as the higher doses. This 
provides useful clinical data to show that with gemfibrozil treatment in 
hypertriglyceridaemic patients, a large dose may not be required to control the blood 
lipids. In general, gemfibrozil 300 mg bd may be adequate to control serum triglyceride 
levels in many patients. This may avoid the side effects seen with large doses ofthe drug 
which could not be tolerated in some patients. 
The results of this study are comparable with previous studies. Gemfibrozil can 
effectively lower the serum triglyceride level and increase HDL-cholesterol. These data 
agree with the available data in Caucasians (Todd and Ward, 1988; Illingworth, 1993; 
Klowiewicz-Latoszek et al, 1991) and another study in Hong Kong (Ko et al，1995). 
The LDL-cholesterol appeared to rise in some patients although this is difficult to 
assess because LDL-cholesterol could not be calculated in many patients at baseline 
because ofthe high triglyceride levels. The patients included in this study were mainly of 
Type IIa, IIb, and IV(mild) hyperlipidaemia. Gemfibrozil may reduce LDL-cholesterol 
depending on the type ofhyperlipidaemia. It can reduce LDL-cholesterol in type IIa but 
raise LDL-cholesterol in types IIb and type IV hyperlipidaemia (Davignon, 1994). 
Previous clinical studies with gemfibrozil have generally used doses ranging from 
800 to 1200 mg daily (Todd and Ward, 1988). There appeared to be no additional 
- i 
benefit increasing the dose to 1600 mg per day (Weisweiler, 1978) Most of the larger 
double-blind placebo-controlled studies used doses of gemfibrozil of 1200 or 1600 mg 
per day in patients of Type IIa, IIb or IV hyperlipidaemia (Todd and Ward, 1988) and 
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serum triglycerides were decreased by 40 - 60% and total cholesterol by up to 22% and 
HDL-cholesterol increased by up to 25%. The Helsinki Heart Study used a fixed dose of 
600 mg twice daily of gemfibrozil (Frick et al, 1987) and showed a reduction in cardiac 
end points after 5 years although there was no change in overall mortality. Some other 
studies have shown reductions in apolipoprotein B with gemfibrozil (Betteridge et al, 
1994) but like the changes in total cholesterol and LDL-cholesterol the effects on 
apolipoprotein B are probably dependent on the type of hyperlipidaemia and reductions 
in apolipoprotein B are more likely to be seen in patients with type IIa hyperlipidaemia. 
In this study, the patient's age range was from 34 to 75 years old, with a mean age 
of 56.5 years with 6 males and 15 females. The results suggest that the effect of the dmg 
did not depend on the age or sex of the patients. Also, it did not significantly affect the 
liver function or renal function even in the elderly patients. This drug therefore can 
effectively control hypertriglyceridaemia even in relatively small doses. 
Although this study was not performed as an ideal parallel group placebo-
controlled study, there was a control mn-in period before the active treatment. Any 
previous lipid-lowering treatment was stopped and patients were instructed by the 
dietitian on a lipid-lowering diet which was followed for 6 weeks before active treatment 
was commenced. However, after 12 weeks active treatment with gemfibrozil, the serum 
triglyceride was markedly reduced and total cholesterol and was also decreased and 
HDL-cholesterol increased. 
j 
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Chapter 5. Gemfibrozil 900 mg tablet study 
5.1. Assessment of the efficacy and tolerability of a new formulation of gemfibrozil 
as a 900 mg tablet in the treatment ofhyperlipidaemia 
Various types of hyperlipidaemia are treated with gemfibrozil and it has been 
proven to reduce the incidence of coronary artery disease. Previously, it was available in 
a capsule formulation and it was required to be taken twice daily. The large capsule 
might be difficult for some patients to swallow and multiple daily dosing may reduce 
compliance. Therefore, a new tablet formulation containing 900 mg gemfibrozil which 
was effective with once daily dosing was produced but it had only just become available 
in Hong Kong at the time this study was commenced. The 900 mg tablet had been found 
to be similar in efficacy to 600 mg twice daily of the old formulation in studies in 
western countries (Schwartzkopff et al, 1985; Kovanen et al, 1986; Avema et al, 1991) 
and a study in diabetic patients with dyslipidaemia in Hong Kong has shown similar 
findings (Ko et al, 1995) 
This study was conducted to assess the effects of this new tablet formulation on 
the detailed lipid profile and to assess its tolerability in Chinese patients with 
hyperlipidaemia. It is mainly indicated in patients with either mixed hyperlipidaemia or 
hypertriglyceridaemia. 
5.2. Patients recruited 
A total of25 patients were recruited. They had either: 
a) elevated total cholesterol (>6.5 mmol/1) due to elevation of LDL-cholesterol (>4.5 
mmol/1) along with moderately elevated triglycerides (>2.3 mmol/1) and a low level 
ofHDL-cholesterol (<1.0 mmol/1 in women, <0.8 mmol/1 in men) 
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b) moderate elevation of triglyceride (>2.3 mmol/1) with normal LDL-cholesterol (<3.5 
mmol/1) but low HDL-cholesterol and an additional cardiovascular risk factors such 
as hypertension and diabetes or 
c) severe elevation of triglyceride (>6 mmol/1) alone. 
The nature and purpose of the study was explained to suitable patients and written 
consent was obtained. This study included 18 female and 7 male Chinese patients. Their 
mean age was 56.4 years with a range from 35 to 75 years. Any previous lipid-lowering 
therapy was stopped and the patients were instructed by a dietitian on a lipid lowering 
diet and weight loss if appropriate before active treatment was instigated. The details of 
the patients are shown in Table 5.1. 
From the group, 16 patients had hypertension treated mainly with calcium 
antagonists and 4 patients had NIDDM on diet and oral hypoglycaemic agents. Patients 
with ischaemic disease such as myocardial infarction or cerebrovascular disease, those 
with any other serious illness which might interfere with the conduct ofthe trial or those 
with critical impairment ofliver function test were excluded. 
5.3. Methods 
The fasting plasma lipid levels were measured after six weeks on diet and active 
treatment was commenced if the lipid profile was within the range defined above on two 
separate occasions at least 1 week apart. Gemfibrozil tablets 900 mg once daily were 
started and the patients reviewed at 4, 8 and 12 weeks. The details of the lipid 
measurements have been given previously. 
5.4. Results 
5AA, Tolerability 
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Although 25 patients were recruited, only 20 completed the study. One patient 
defaulted, two patients withdrew due to constipation and/or abdominal discomfort and 
another two patients withdrew due to dizziness. In the remaining 20 patients the drug was 
well tolerated with few side effects related to treatment although a large number ofmild 
side effects were recorded throughout the study in response to the detailed side effect 
questionnaire (Table 5.2). 
5.4.2. Efficacy 
The results for the plasma lipid profile, apo AI, apo B and lipoprotein Lp(a) are 
shown in Tables 5.3 - 5.5. The baseline lipid concentrations were total cholesterol 
6.73土0.33 mmol/l, triglycerides 5.19±0.58 mmol/1 and HDL-cholesterol 1.09±0.06 
mmol/l. LDL-cholesterol levels could only be estimated in 13 patients at baseline 
because ofthe high triglyceride levels. After active treatment, triglycerides were reduced 
(P<0.01) to 2.23t0.25, 2.12±0.28 and 2.48±0.38 mmol/1 and total cholesterol to 
6.23±0.2, 5.92±0.24 and 5.76±0.33 mmol/1 at 4，8 and 12 weeks respectively. The 
changes in cholesterol were not significant on ANOVA. There were increases in HDL-
cholesterol of 18 o/o, 19 % and 14 % respectively at the three visits. These were not 
significant on ANOVA but were significant (^<0.05) if each visit was compared 
separately with the baseline by paired t-test. 
The apolipoprotein AI levels remained unchanged after active treatment but 
apolipoprotein B was slightly reduced from 164.19±8.38 to 151.25±11.20 after 12 weeks 
and lipoprotein Lp(a) showed wide variation with an increase in mean values from 
195.45±68.8 to 274.65±76.20 at 12 weeks. The blood pressure values, both systolic and 
diastolic, were not altered during this study. No changes in liver enzymes, renal 
function, fasting blood glucose or creatine kinase were detected. 
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Table 5.1. Patient details for the gemfibrozil 900 mg tablet study 
SubjectSex Age~~Height Weight ~ 5 i ^ ~ H T DM Additional 
number (m) (kg) (kg/m.m) treatment  
701 F 75 1.50 61.4 27.3 N N 
702 F 59 1.44 83.3 40.2 Y N AT100 odNR20 bd 
703 F 44 1 51 58.2 25.7 Y N EN 20od IND 2.5od PAR 1 tb PIR 1 tb 
704 F 65 1 53 63.6 27.2 N Y DSP100bd,FRU40od,SLK2tb, 
PRX10bd,GEL1tb TNG PRN 
705 F 61 1.51 58.1 25.5 Y N NR20bd 
706 F 66 1.45 43.8 20.8 Y N DTZ60bd 
707 F 65 1.46 46.1 21.8 Y N EN10odNR40 bd 
708 F 66 1.58 64.0 25.8 N N 
709 F 46 1.57 67.4 27.5 Y N DX4odAT50 od ALP 200 od 
710 M 43 1.53 78.7 33.6 Y N NR20bd 
711 F 63 1.48 42.9 19.6 N N RAN 150 bd 
712 M 50 1.74 77.0 25.4 N N 
713 F 65 1.51 49.6 21.9 Y Y NR 40 bd PRZ 0.5 bd 
714 M 47 1.60 65.2 25.5 Y N AT 50 od ALP 300 od 
7 1 5 M 44 1.59 82.4 32.6 Y Y EN 10od MTP 200 od 
716 F 61 1.46 44.5 20.9 Y Y AT100 od DX40 od 
717 F 73 1.58 60.9 24.4 Y N NR 20 bd 
718 M 35 1.74 88.5 29.2 Y N EN10odlND2.5odNR20bd 
719 F 74 1.48 54.9 25.1 Y N DTZ30tds 
720 F 54 1.53 59.4 25.4 Y Y DTZ 60 bd GB 5 od MTP 100 od 
721 M 38 1.64 72.7 27.0 N N 
722 M 42 1.73 76.3 25.5 Y N NR 20 bd 
723 F 51 1.62 56.0 21.3 N N EST 2 od 
724 F 61 1.59 71.6 28.3 N N 
725 F 63 1.52 54.2 23.5 N N 
N 7M 25 25 25 25 16 4 
MEAN 18F 56.44 1.55 63.23 26.04 
SD 11.65 0.09 13.05 4.50 
SEM 2.33 0.02 2.61 0.90 
Drug abbreviations: 
ALP = Allopurinol END � Indapamide C^atrilix) 
AT = Atenolol MTP = Metoprolol 
DSP � Disopyramide NR = Nifedipine retard 
DTZ = Diltiazem PAR � Paracetamol (panadol) 
DX � Doxazosin PIR = Piriton 
EN = Enalapril PRX � Piroxicam (Feldene) 
EST = Estrogen RAN = Ranitidine 
FRU = Frusemide SLK = Slow K 
GEL 二 Gelusil VER 二 Verapamil (Isoptin) 
GB � Glibenclamide 
od 二 om;e daily, bd 二 twice daily, tds = three times daily. 
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Table 5.2. Side effects reported by the patients during the gemfibrozil 900 mg 
tablet study 
side effects Y1 Y2 Y3——V4 
n = 25 n = 25 n = 23 n = 2l 
headache 8 6 3 4 
dizziness 5 6 7 4 
faintness 2 0 0 0 
fatigue 10 8 8 5 
sleepiness 9 9 8 5 
flushing 1 1 0 0 
cold fingers or toes 0 1 0 0 
swelling of feet or ankles 5 3 3 2 
abnormal weight gain 0 0 0 1 
rapid heartbeat 4 3 1 2 
slow heartbeat 1 0 0 0 
shortness ofbreath 6 2 0 3 
cough 11 8 4 3 
sputum 12 8 5 7 
nausea / vomiting 3 1 2 0 
heartbum 3 4 7 4 
abdominal pain 2 2 (1) 3(1) 
diarrhoea 3 3 1 2 
skin rash 3 3 3 2 
lose of taste 1 2 3 2 
hair loss 5 9 6 4 
dry eyes 5 2 3 5 
dry mouth 5 2 4 2 
difficulty in remembering things 16 10 10 6 
inability to concentrate 4 4 1 1 
abnormal moodswing 3 4 7 5 
depressed 5 4 6 4 
unable to fall asleep 6 2 6 4 
numbness or tingling in hands/feet 12 10 7 8 
nightmares 3 1 3 5 
waking up during night 14 11 11 9 
increased frequency of urination 4 4 1 4 
impotence 0 0 0 0 
decrease libido 14 15 9 10 
muscle cramp 4 5 3 1 
stiffness in muscle 3 4 2 2 
difficulty walking 1 1 0 0 
Drug withdrawal 0 / 0 2 2 
Total no. ofside effects Tn TSS lM U6 
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Table 5.3. Plasma total cholesterol and tyriglycerides during the gemfibrozil 900 
mg tablet study 
Total cholesterol Triglycerides 
SUB# VI V2 V3 V4 SUB# VI V2 V3 V4 
701 6.6 5.7 6 5.7 701 7.72 1.91 2.14 2.59 
702 5.8 5.4 4.2 4.1 702 1.49 1.48 0.91 0.65 
703 6.5 5.7 5.5 4.4 703 5.15 1.02 1.31 1.2 
704 5.2 5.1 5.9 5.2 704 3.2 3.53 2.7 4.87 
705 66 7.4 6 6.4 705 3.25 1.81 2.56 2.17 
706 7.8 7.2 7.1 7.2 706 4.66 1.41 3.18 2.59 
707 7.1 6.6 7.2 6.6 707 3.19 1.72 1.11 1.31 
708 8.8 6.3 5.5 5.3 708 12 2.81 2.6 2.51 
709 5 4 6.3 5.8 5.9 709 4.16 1.78 0.73 1.69 
710 7 6 7 6.4 710 3.08 3.56 2.22 
711 8.8 7.6 711 1.27 0.89 
712 6.2 5.7 5.7 5.5 712 9.28 4.47 5.35 5.69 
713 5.7 5.5 4.8 5.1 713 6.91 3.8 1.63 1.53 
714 3.3 3.2 3.3 3.6 714 2.58 1.35 1.3 6.36 
715 3 4 4 4.8 4.2 715 2.84 1.57 1.71 2.08 
716 5.7 6.2 5.4 716 7.37 3.25 4.92 
717 7.5 7.3 7.3 6.9 717 8.38 1.84 1.22 2.3 
718 7 6 7.6 6.8 6.3 718 4.78 2.18 1.35 4.54 
719 6.3 7.8 719 4.1 5.18 
720 6.3 5.7 5.2 720 3.99 1.45 3.08 
721 8.5 9.3 8.2 10.5 721 2.75 1.16 0.75 0.87 
722 6.4 6.3 7.4 6.5 722 6.46 4.18 4.45 3.58 
723 8 4 4.8 5 4.6 723 11.53 1.18 1.2 1.19 
724 10.9 5.9 5.9 5.4 724 6.3 1.33 1.32 1.09 
725 5.8 6.1 6.7 5.7 725 3.29 0.97 1.03 0.79 
N 25 25 23 20 N 25 25 23 20 
MEAN 6.73 6.23 5.92 5.76 MEAN 5.19 2.23* 2.12* 2.48* 
SD 1.67 1.29 1.13 1.49 SD 2.90 1.24 1.33 1.68 
SEM 0.33 0.26 0.24 0.33 SEM 0.58 0.25 0.28 0.38 
* p <0.05 compared to baseline. 
i 
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Table 5.4. Plasma HDL-cholesterol and LDL-cholesterol levels during the 
gemfibrozil 900 mg tablet study 
HDL-cholesterol LDL-cholesterol 
SUB# VI V2 V3 V4 SUB# VI V2 V3 V4 
701 0.79 1.3 1.3 1.28 701 3.5 3.7 3.2 
702 0.98 0.96 1.06 1.07 702 4.1 3.8 2.7 2.7 
703 1.16 1.33 1.35 1.2 703 3.9 3.6 2.7 
704 0.8 0.99 1.08 0.81 704 2.9 2.5 3.6 
705 0.96 1.45 0.93 0.94 705 4.2 5.1 3.9 4.5 
706 1.64 1.51 1.53 1.77 706 5 4.1 4.3 
707 1.34 1.25 1.29 1.31 707 4.3 4.6 5.4 4.7 
708 0.7 1.23 1.19 1.19 708 3.8 3.1 3 
709 1.06 1.27 1.32 1.27 709 2.4 4.2 4.1 3.9 
710 1.41 1.3 1.29 710 4.8 4.1 4.1 
711 1.38 1.39 711 6.8 5.8 
712 0.83 0.65 0.76 0.73 712 3 
713 0.81 1.3 0.94 1.02 713 2.5 3.1 3.4 
714 1.53 0.76 0.77 0.63 714 0.6 1.8 1.9 
715 0.75 0.91 0.98 0.93 715 1.4 2.4 3 2.3 
716 0.71 0.84 0.92 716 3.9 
717 1.04 1.36 1.45 1.23 717 5.1 5.3 4.6 
718 1.42 1.53 1.42 1.29 718 5.1 4.8 
719 1.23 1.57 719 3.2 
720 1.18 1.19 0.94 720 3.3 3.9 2.9 
721 0.92 1.4 1.57 1.65 721 6.3 7.4 6.3 8.5 
722 1.01 0.99 1.02 1.02 722 3.4 4.4 3.9 
723 1.46 1.46 1.48 1.36 723 2.8 3 2.7 
724 0.99 1.47 1.5 1.58 724 3.8 3.8 3.3 
725 1.12 1.13 1.33 1.32 725 3.2 4.5 4.9 4 
N 25 25 23 20 N 13 24 21 16 
MEAN 1.09 1.22 1.19 1.18 MEAN 3.65 4.00 3.89 3.86 
SD 0.28 0.25 0.25 0.30 SD 1.74 1.24 1.04 1.45 
SEM 0.06 0.05 0.05 0.07 SEM 0.48 0.25 0.23 0.36 
no significant change on ANOVA 
_ ,) 
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Table 5.5. Plasma apo AI, apo B and Lp(a) levels during the gemfibrozil 900 mg 
tablet study 
apo Al apo B 
Subject# baseline 4wks 8wks 12wks subject# baseline 4wks 8wks 12wks 
701 122 151 154 145 701 127 140 154 138 
702 124 133 134 130 702 175 154 112 106 
703 154 145 149 131 703 163 150 154 108 
704 133 147 154 148 704 126 141 161 139 
705 137 165 115 124 705 183 216 146 186 
706 206 159 156 185 706 210 219 186 206 
707 155 154 154 149 707 205 173 192 182 
708 111 139 132 131 708 94 91 80 
709 153 147 146 151 709 131 174 154 166 
710 165 153 149 710 220 208 199 
712 118 103 108 117 712 134 168 163 137 
713 146 137 126 135 713 166 154 145 157 
714 114 112 113 120 714 91 92 87 96 
715 132 137 129 715 116 134 120 
716 120 105 112 716 148 172 138 
717 145 154 156 151 717 138 194 189 188 
718 152 151 136 152 718 201 221 190 199 
720 134 131 125 720 184 157 155 
721 124 130 149 161 721 252 232 210 282 
722 118 106 103 99 722 165 183 209 194 
723 163 108 149 153 723 148 81 115 111 
724 131 145 88 138 724 133 103 57 84 
725 142 137 117 140 725 148 190 150 146 
Count 22 23 23 20 Count 21 23 23 20 
Mean 139.41 136.70 133.13 139.45 Mean 164.19 162.26 151.78 151.25 
SD 22.04 18.53 19.87 18.44 SD 38.39 43.80 39.98 50.09 
SEM 4.59 3.86 4.14 3.85 SEM 8.00 9.13 8.34 10.45 
Lp(a) 
Subject# baseline 4wks 8wks 12wks 
701 47 140 196 282 
702 142 175 191 165 
703 121 226 146 48 
704 100 145 141 85 
705 274 278 280 441 
706 309 729 409 421 
707 324 416 476 394 
708 28 81 84 79 
709 20 117 104 97 
710 212 114 103 
712 12 20 16 11 
713 1565 1316 1612 1585 
714 25 110 91 80 
715 146 141 109 
716 220 479 226 
717 31 290 337 246 
718 206 195 259 189 
720 27 62 39 
721 58 77 96 107 
722 64 191 200 294 
723 277 283 431 344 
724 75 72 52 58 
725 163 526 499 458 
Count 22 23 23 20 ,) 
Mean 195.45 269.04 266.48 274.65 I 
SD 322.72 285.88 325.47 340.78 
SEM 67.29 59.61 67.87 71.06 
no significant change on ANOVA 
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5.5. Discussion 
The results show that the 900 mg tablet of gemfibrozil is effective in reducing 
blood triglyceride levels with an accompanying increase in HDL-cholesterol. Its efficacy 
did not vary much over the 12 weeks of the study suggesting the maximum effect can be 
seen by 4 weeks. It slightly reduced the semm total cholesterol but LDL-cholesterol 
appeared to remain the same after treatment as with the gemfibrozil titration study. This 
is difficult to assess because LDL-cholesterol levels cannot be calculated accurately for 
all patients at the baseline visit before starting treatment. There were no obvious 
alterations of apolipoproteins, blood pressure, fasting blood glucose, liver function and 
renal function after active treatment although other dmgs were used to control the blood 
pressure and glucose of some patients throughout the study but the doses of these were 
not altered. 
Earlier studies with preparations of gemfibrozil tablets of 900 mg once daily 
showed similar efficacy to twice daily dosage of 600 mg with substantial reductions in 
cholesterol, triglycerides, LDL-cholesterol and apolipoprotein B and increases in HDL-
cholesterol and its subfractions HDL: and HDL3 as well as in apolipoproteins AI and AII 
(Kovanen, 1986). This was performed in Finnish men with predominant elevations of 
LDL-cholesterol. Another study in Italy compared these 2 dosage regimens in 48 
subjects with raised total cholesterol and/or triglycerides (16 Type IIa, 12 Type IIb, 16 
Type IV) and found similar efficacy with the two treatments (Avema et al, 1991). The 
900 mg tablet reduced total cholesterol by 19.^%, triglycerides by 44.8%, LDL-
cholesterol by 19.9% and apolipoprotein B by 16.5% and increased HDL-cholesterol by 
15% and apolipoprotein AI by 9.7%. 
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The study from Hong Kong (Ko et al, 1995) also showed that the 900 mg tablet 
showed similar efficacy to the conventional 600 mg twice daily regimen in Chinese 
NIDDM patients with dyslipidaemia. They found significant decreases of 47.5% in 
triglycerides and increases of 14.3% in HDL-cholesterol but no change in total 
cholesterol or in glycaemic control assessed by fasting plasma glucose and HbAi^, 
although there was a slight tendency for both these to increase. They also found an 
increase in fibrinogen of 45% and 31% with the 600 mg twice daily and 900 mg once 
daily doses respectively. Previous reports regarding the effect of gemfibrozil on 
fibrinogen have produced conflicting results (O'Brien et al, 1982; Avellone et al, 1988; 
Anderson et al, 1990; Stringer et al, 1990; Branchi et al, 1993) and on average it has little 
or no effect (Davignon, 1994). However, it may improve fibrinolytic capacity by 
inhibiting plasminogen activator inhibitor-1 (PAI-1) (Anderson et al, 1990) 
The present results for lipids and glucose are similar to those previously reported 
in the diabetic patients from Hong Kong (Ko et al, 1995). The findings in the studies 
from westem countries of greater reductions in total cholesterol and LDL-cholesterol 
probably reflect the type of patient involved in the study rather than any ethnic 
difference. Patients with higher starting levels of LDL-cholesterol appear to be more 
likely to show a reduction in this 
In the majority of patients after taking gemfibrozil 900 mg once daily for 4 
weeks, the serum triglyceride level decreased to within the normal range independent of 
the patient's age. Therefore, this constant dose Wth once daily dosing may be an 
advantage to use in some elderly patients because the elderly patients easily forget to take 
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the drug and they may find it difficult to accept increasing doses or to take the drug 
several times daily. 
The side effects reported with this dose of gemfibrozil were similar to those in the 
gemfibrozil titration study and included such things as fatigue, sputum production, 
numbness or tingling in hands or feet and decreased libido. The number of withdrawals 
from the study was slightly greater than in the titration study but it is difficult to make 
definite comparisons. From the results of this study, the new tablet formulation of 900 
mg gemfibrozil appears effective with once daily dosing and has quite good tolerability 
and this can lead to improvement in the patients' compliance and acceptability. 
In this study, there was a run-in control period of 4 weeks prior to active lipid-
lowering treatment. Prior to this period, dietary advice was given to the patients. The 
patients' lipid levels rose when any previous drug treatment was stopped and then 
remained high and fairly constant until the study drug treatment was started, providing 
some evidence that the effects seen were due to the drug treatment and not to other 
interventions. 
:) 
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Chapter 6. Bezafibrate study 
6.1. Assessment of the efficacy and tolerability of bezafibrate in the treatment of 
hyperlipidaemia 
6.2. Introduction 
Various types of hyperlipidaemia can be treated with bezafibrate, another of 
the flbrate group of drugs. It has recently been shown to reduce the progression of 
coronary artery disease in young male myocardial infarction survivors in the 
Bezafibrate Coronary Atherosclerosis Intervention Trial (BCAIT; Ericsson et al, 
1996). Some groups of patients with diabetes mellitus have been shown to respond to 
this drug with improved glycaemic control (Jones et al, 1990; Mikhailidis et al, 1990). 
Abnormalities of the coagulation system and platelet activity are associated 
with hyperlilpidaemia, particularly hypertriglyceridaemia, and also with hypertension 
and the metabolic syndrome. The treatment of hypertension or hyperlipidaemia may 
alter the coagulation factors. Therefore, we assessed coagulation by measuring 
fibrinogen levels to determine whether these were altered by treatment with 
bezafibrate. Previous studies have shown a beneficial effect (Almer and Kjellstrom, 
1986; Pazzucconi et al, 1992). 
We conducted this study to determine the efficacy and tolerability of the 400 
mg retard tablets of bezafibrate by examining the effects on the detailed lipid profile, 
glycaemic control and the coagulation system in patients with mixed hyperlipidaemia 
or hypertriglyceridaemia. 
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6.3. Patients 
A total of23 patients were recruited into this study. They had either: 
a) elevation of total cholesterol (>6.5 mmol/l) due to increased levels of LDL-
cholesterol (>4.5 mmol/l) along with moderately elevated triglycerides (>2.3 
mmol/l) and low levels of HDL-cholesterol (<1.0 mmol/1 in women, <0.8 mmol/1 
in men) 
b) moderate elevation of triglycerides (>2.3 mmol/1) with normal LDL-cholesterol 
(<3.5 mmol/1) and low HDL-cholesterol and an additional cardiovascular risk 
factor 
c) severe elevation of triglycerides (>6 mmol/1) alone. 
There were 15 female and 8 male Chinese patients included in this study. The 
nature and purpose of the study were explained to the recruited patients and written 
consent was obtained. Their age ranged from 40 to 67 years and the mean age was 
56.6 years. Patients details are shown in Table 6.1. The previous lipid-lowering 
therapy was stopped for at least 6 weeks before commencing the active treatment 
phase ofthe trial. The patients were instructed by the dietitian on a lipid-lowering diet 
and weight loss and this diet was intended to continue throughout the study. The 
patients taking other medications for stable conditions such as hypertension or 
diabetes remained on constant treatment throughout the study but those taking drugs 
with known interactions with fibrate drug were excluded. 
The patients with recent (within 6 months) |ischaemic events like myocardial 
infarction and cerebrovascular disease, those with any other serious illness known to 
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interfere with the conduct of the trial and those with initial impairment of liver 
function tests were also excluded. The fasting plasma lipid levels were measured after 
6 weeks on diet and active treatment was started if the lipid profile was within the 
range defined above on two separate occasions at least 1 week apart. The patients 
were reviewed at 4, 8 and 12 weeks after the bezafibrate retard tablets 400 mg once 
daily were commenced. 
6.4. Results of bezafibrate study 
6.4.1. Tolerability 
We recruited a total of 23 Chinese patients but only 22 patients completed the 
study with bezafibrate SR 400 mg once daily. One patient was unable to tolerate the 
400 mg dose because of general malaise, distress and palpitation but she was able to 
take a dose of200 mg once daily. The side effects reported by the patients during the 
course of the study are shown in Table 6.2. 
6.4.2. Efficacy 
The results are summarized in Tables 6.3 to 6.5. In the 22 patients who 
tolerated the drug well and completed the study on the full dosage, triglyceride levels 
were reduced (p<0.05) from 8.05±1.53 (mean±SEM) to 3.28±0.57 mmol/1 at 4 weeks 
and then from 4.22±1.68 at 8 weeks to 3.64±0.99 mmol/1 at 12 weeks. As the 
baseline triglyceride levels failed the test for normality of distribution the analysis was 
performed by Kruskal-Wallis one way analysis of yariance on ranks followed by an 
all pairwise multiple comparison procedure (Dunn's Method). 
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HDL-cholesterol levels showed a significant (jp = 0.0208) change on Kruskal-Wallis 
one way analysis of variance on ranks and all pairwise multiple comparison showed a 
significant ^X0.05) increase from 1.04±0.12 to 1.22±0.07 after 8 weeks. There was 
no significant change in total cholesterol or LDL-cholesterol by ANOVA. Total 
cholesterol was unaltered from 6.94±0.39 at baseline to 6.81土0.49 mmol/1 at 12 
weeks. LDL-cholesterol could only be calculated in 8 subjects at baseline because of 
the high triglyceride levels. 
Both fasting blood glucose and glycosylated haemoglobin (HbAlc) were not 
significantly altered, fasting blood glucose falling from 5.48±0.16 to 5.46±0.15 
mmol/1 at 4 weeks and 5.28±0.16 and 5.33±0.18 at 8 and 12 weeks respectively. 
HbAlc fell from 5.85±0.16 to 5.83±0.23 mmol/1 after 12 weeks. Fibrinogen levels 
were significantly (^<0.001) reduced from 3.05±0.13 to 2.49±0.07 g/1 after 12 weeks. 
There was no significant change in alanine transaminase levels or any of the 
other liver function tests except for alkaline phosphatase which was significantly 
reduced at each visit on treatment. Mean creatine kinase levels did not change 
throughout the study although some subjects had levels which were moderately 
elevated before treatment and the elevation persisted. 
/ 
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Table 6.1. Patient details for the bezafibrate study 
Subject~~Se^ fi^ Heigi^~"Weight B i ^ HT~~DM Additional 
number (m) (kg) (kg/m.m) treatment  
1 F 64 1.5 47.0 21.8 Y N DTZ60bd, RAN 150od 
2 F 66 1.5 47.5 22.6 Y N NR 40bd, EN 20od 
3 F 63 1.5 45.5 21.3 Y Y AT 100od, GB 10/5, DX 80od, ISD 10od 
4 F 67 1.5 65.0 27.4 N Y DSP 100bd, FRU 40od, SLK 2tb, ASP 
80od 
5 F 67 1.6 64.0 26.0 Y N EN 20od, FRU 40od 
6 F 48 1.6 70.0 28.8 Y N SAL 4od, IND 2.5od, DX 4od, ALP 
200od 
7 F 65 1.6 70.2 27.8 N N 
8 M 40 1.6 76.0 30.1 N N 
9 M 51 1.7 79.1 26.4 N N PRX 10prn 
10 F 52 1.6 56.2 22.0 N N EST2od 
11 F 60 1.6 61.4 24.3 Y N NR40bd 
12 F 75 1.5 59.1 25.6 Y N EN5bd 
13 M 45 1.6 83.2 32.9 Y Y EN 10od, MTP 200od 
14 M 47 1.6 66.6 27.4 Y N AT 50 od, ALP 300od 
15 M 40 1.6 74.8 27.8 N N 
16 M 44 1.6 59.8 24.6 N N 
17 F 63 1.5 59.0 25.5 Y N NR 20bd 
18 F 53 1.5 62.0 26.5 Y Y DTZ 60 bd, GB 5 od, MTP 100 od 
19 F 63 1.6 66.0 26.1 Y Y ASP 160od, NR 20bd, ISD 40od, MTP 
50bd, MAX 10tds 
20 M 43 1.7 77.0 26.0 Y N NR 40bd, EN 5od 
21 F 64 1.5 55.6 24.1 N N 
22 M 56 1.7 62.0 22.5 N N 
23 F 66 1.5 49.6 22.3 Y Y NR 40od, PRZ 0.5bd 
N 8M/15F 23 23 23 23 13 5 
MEAN 56.61 63.33 1.57 25.64 
SD 10.24 10.50 0.07 2.88 
SEM 2.14 2.19 0.02 0.60 
Drug abbreviations: 
ALP = Allopurinol IND = Indapamide CNatrilix) 
AT = Atenolol MTP = Metoprolol 
DSP = Disopyramide NR = Nifedipine retard 
DTZ = Diltiazem PAR = Paracetamol (panadol) 
DX = Doxazosin PRX = Piroxicam (Feldene) 
EN = Enalapril RAN = Ranitidine 
EST = Estrogen SLK = Slow K 
FRU = Fmsemide 
GB 二 GHbenclamide 
od = once daily, bd 二 twice daily, tds = three times daily. 
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Table 6.2. Side effects reported by patients in the bezafibrate study 
side effects Y] Y2 V3 YA 
n = 23 n = 23 n = 23 n = 23 




sleepiness 4 1 
flushing 1 
cold fmgers or toes 
swelling of feet or ankles 2 1 
abnormal weight gain 
rapid heartbeat 1 
slow heartbeat 
shortness ofbreath 
cough 1 2 1 
sputum 
nausea / vomiting 
heartburn 








difficulty in remembering things 
inability to concentrate 
abnormal mood swing 
depressed 
unable to fall asleep 1 
numbness or tingling in hands/feet 1 1 
nightmares 
waking up during night 




stiffness in muscle 
difficulty waUcing 
chest pain 1 
tremor 1 
swelling of fmgers 1 
Drug withdrawal 0 0 0 0  
Total no. ofside effects 2 ~ [ s 6 4  ^  
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Table 6.3. Plasma lipids during the bezafibrate study 
Total cholesterol Triglycerides 
SUB#baseline 4wks 8wks 12wks SUB#baseline 4wks 8wks 12wks 
2 6.9 9.2 9.9 9.7 2 4.48 1.71 1.61 1.71 
3 6.1 6 6.3 6.2 3 4.34 2.58 2.27 2.59 
4 4.7 5.5 5.9 5.9 4 3.66 2.75 3.24 2.45 
5 8.7 6.7 6.9 6 5 7.76 3.33 2.96 2.44 
6 8.5 6.6 6.5 5.9 6 13.39 3.91 5.35 2.86 
7 10 6.7 5 6.1 7 3.75 2.56 1.04 1.72 
8 11.7 8.3 15.7 14.5 8 36 11.15 39.1 23.2 
9 5.5 5.8 6.1 6 9 6.43 5.02 5.09 3.36 
10 7.5 5.6 4.9 5.4 10 5.83 1.41 1.13 1.47 
11 7.7 6.4 6.7 6.6 11 9.49 1.72 1.64 1.58 
12 8.6 5.6 5.4 5.4 12 8.98 2.59 2.56 1.89 
13 4.6 5 5 4.5 13 4.6 1.74 3.12 3.81 
14 3.8 3.9 3.4 3.5 14 6.81 2.55 2.83 3.24 
15 7.2 10.7 8.7 10.3 15 2.3 10.93 1.1 1.43 
16 6.9 6.4 6.4 6.3 16 13.47 2.43 2.93 6.55 
17 6.1 7.3 7.5 8.1 17 4.72 2.36 2.43 2.73 
18 6.7 6.9 6.5 7.1 18 3.5 2.52 2.51 3.91 
19 6 5.7 6 19 3.97 2.22 1.63 
20 5.6 6.2 6.2 7.1 20 6.76 2.83 3.1 2.79 
21 6.1 7.2 6.6 6.5 21 3.23 0.37 1.51 2.05 
22 6.9 5.4 6.1 5.6 22 14.82 2.61 3.42 2.41 
23 6.9 6.5 6.1 6.3 23 8.82 2.85 2.25 2.35 
Count 22 22 22 21 Count 22 22 22 21 
Mean 6.94 6.53 6.72 6.81 Mean 8.05 3.28* 4.22* 3.64* 
SD 1.81 1.45 2.39 2.32 SD 7.17 2.67 7.87 4.62 
SEM 0.39 0.31 0.51 0.49 SEM 1.53 0.57 1.68 0.99 
HDL-cholesterol LDL- cholesterol 
SUB#baseline 4wks 8wks 12wks SUB#baseline 4wks 8wks 12wks 
2 0.88 1.68 1.62 1.63 2 4 6.8 7.5 7.3 
3 0.7 1.04 1.05 1.1 3 3.4 3.8 4.2 3.9 
4 0.75 0.88 0.89 0.87 4 2.3 3.4 3.5 4 
5 0.62 1.1 1.27 1.28 5 4.1 4.2 3.6 
6 2.44 1.15 1.11 6 3.7 3.5 
7 1.26 1.37 1.78 1.64 7 7 4.2 2.8 3.7 
8 0.59 1.71 8 
9 0.65 0.66 0.7 9 3.8 
10 1.15 1.74 1.61 1.59 10 3.2 2.8 3.1 
11 0.78 1.43 1.67 1.59 11 4.2 4.3 4.3 
12 0.82 1.28 1.41 1.47 12 3.1 2.9 3.1 
13 0.72 1.1 0.97 0.73 13 3.1 2.6 2.1 
14 0.58 0.28 0.72 0.76 14 1.9 1.4 1.3 
15 0.98 1.12 1.39 15 5.2 7.1 8.3 
16 2.71 1.03 0.9 16 4.2 4.2 
17 0.82 1.34 1.39 1.55 17 4.9 5.1 5.3 
18 1.02 1.12 1.23 1.14 18 4.1 4.6 4.1 4.1 
19 0.85 1.17 1.33 19 3.3 3.5 3.9 
20 0.7 0.81 0.83 0.91 20 4.1 4 4.9 
21 1.06 1.25 1.2 1.53 21 3.5 5.3 4.7 4 
22 2 1.05 0.97 0.99 22 3.1 3.5 3.5 
23 0.82 1.07 1.17 0.93 23 4.2 3.9 4.3 
Count 22 21 19 19 Count 8 19 19 19 
Mean 1.04 1.16 1.22* 1.21 Mean 4.10 3.97 4.04 4.11 
SD 0.58 0.34 0.31 0.34 SD 1.43 1.03 1.44 1.58 
SEM 0.12 0.07 0.07 0.07 SEM 0.31 0.22 0.31 0.34 
* p <0.05 compared to baseline 
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Table 6.4. Plasma glucose, HbAic and fibrinogen during the bezafibrate study 
Plasma glucose HbAjc 
SUB# baseline 4wks 8wks 12wks SUB# baseline 12wks 
2 5.7 5.8 5.7 5.2 2 6.7 6.7 
3 7.8 6.4 6.3 5.5 3 6 
4 5.8 5.7 5.3 5.6 4 5.7 5.5 
5 4.9 4.7 4.9 5 5.7 6.2 
6 6.4 6.8 6.9 6.7 6 6.5 6.8 
7 5.2 5.5 5 5.2 7 5.7 6.1 
8 5 5.2 4.5 5.6 8 6.2 6 
9 5.1 5.1 4.7 5.2 9 6 
10 4.8 5.2 5.3 5 10 5.4 5.7 
11 5.2 4.9 5 4.8 11 4.7 5.6 
12 5 5.3 4.7 4.7 12 4.7 4.7 
13 6.5 6.8 6.8 8 13 6.6 7.5 
14 4.7 4.6 4.7 4.5 14 5 5 
15 5.1 4.5 4.8 5.1 15 6.2 2.6 
16 5.2 4.5 4.5 4.5 16 4.4 4 
17 4.8 4.5 4.8 5 17 5.9 6.3 
18 6.3 5.5 5.6 5.5 18 6.8 7.1 
19 5.1 5 4.6 4.1 19 5.7 5.8 
20 5.3 5.5 5.3 5.4 20 5.6 5.6 
21 5.8 5.7 5.2 5.2 21 6.7 6.7 
22 5.3 5.5 5 5.2 22 5.6 5.9 
23 6.7 6.7 6.4 23 7 6.7 
Count 21 21 22 22 Count 21 21 
Mean 5.48 5.46 5.28 5.33 Mean 5.85 5.83 
SD 0.75 0.73 0.76 0.83 SD 0.74 1.10 
SEM 0.16 0.15 0.16 0.18 SEM 0.16 0.23 
Fibrinogen 
SUB# baseline 12wks 
2 2.8 2.5 
3 3 2.5 
4 2.9 2.9 
5 3.7 2.4 
6 2.7 2.9 
7 3 2.8 
8 2.9 3.1 
9 2.4 2.7 
10 2.1 1.8 
11 4.9 2.5 
12 4.2 2.4 
13 2.7 3 
14 3.3 2.24 
15 2.4 2.1 
16 3.6 2.6 
17 3 2.2 
18 3 2.3 
19 2.8 2.1 
20 3 2.7 
21 3 2.5 
22 2.6 2.47 
23 3 2.1 
Count 22 22 
Mean 3.05 2.49* 
SD 0.61 0.33 
SEM 0.13 0.07 
* p <0.05 compared to baseline 
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Table 6.5. Liver function tests and creatine phoshokinase(CPK) during the 
bezafibrate study 
Alkaline phosphatase Alanine aminotransferase 
Sub# baseline 4wks 8wks 12wks Sub# baseline 4wks 8wks 12wks 
2 93 68 57 2 32 29 28 
3 88 60 58 71 3 30 33 36 37 
4 109 96 85 65 4 47 38 39 37 
5 81 54 46 31 5 28 34 31 
6 30 32 30 27 6 51 49 41 
7 53 37 67 43 7 29 32 41 31 
8 74 47 76 78 8 66 
9 96 74 65 68 9 45 43 43 42 
10 47 43 37 35 10 28 27 32 22 
11 150 88 87 81 11 33 45 34 
12 70 39 43 34 12 28 30 28 21 
13 59 54 50 61 13 62 46 46 44 
14 79 51 57 54 14 27 26 18 
15 46 71 43 44 15 38 40 28 
16 94 76 68 72 16 38 36 40 45 
17 92 62 59 57 17 29 25 26 18 
18 59 56 52 47 18 39 33 40 27 
19 110 92 64 62 19 39 41 31 28 
20 88 79 76 72 20 39 25 39 28 
21 72 60 49 49 21 25 25 29 25 
22 97 77 77 80 22 52 45 46 44 
23 104 95 78 66 23 30 28 33 22 
Count 22 21 22 22 Count 17 20 21 21 
Mean 81.41 63.95* 60.68* 57.00* Mean 37.06 35.60 36.76 31.00 
SD 26.65 19.51 15.72 16.37 SD 9.95 10.55 7.05 8.73 
SEM 5.68 4.16 3.35 3.49 SEM 2.12 2.25 1.50 1.86 
CPK 
Sub# baseline 4wks 8wks 12wks 
2 73 69 70 
3 34 47 52 61 
4 96 91 217 89 
5 100 101 93 
6 45 54 64 51 
7 186 156 287 190 
8 308 239 248 383 
9 139 188 145 375 
10 35 122 116 51 
11 125 119 153 148 
12 70 286 179 125 
13 512 491 361 497 
14 97 131 81 77 
15 139 226 276 131 
16 88 79 95 85 
17 123 161 147 112 
18 58 58 58 55 
19 49 67 50 73 
20 67 83 93 72 
21 59 58 58 53 
22 126 125 129 175 
23 46 65 70 71 
Count 21 21 22 22 
Mean 117.86 140.29 138.59 138.05 ,) 
SD 110.01 104.21 88.16 122.27 '' 
SEM 23.45 22.22 18.79 26.07 
* p <0.05 compared to baseline 
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6.5. Discussion 
Bezafibrate was generally well tolerated in this group of Chinese patients with 
hyperlipidaemia and it produced a marked reduction in triglyceride levels, a moderate 
increase in HDL-cholesterol but no significant change in fasting glucose, glycosylated 
haemoglobin or total cholesterol levels. These lipid data agree with available data in 
Caucasians (Goa et al, 1996) but some previous studies have shown an improvement 
in glycaemic control assessed by fasting glucose levels, fasting semm insulin and C-
peptide (Alberti et al, 1990; Sinzinger et al, 1991; Rovellini et al, 1992; Ohsawa et al, 
1994) and glycosylated haemoglobin decreased in some studies especially when 
glucose control was poor (Onuma et al 1992; Chiba et al, 1993; Ohsawa et al, 1994). 
However, other studies have failed to show changes in some or all of these parameters 
(Riccardi et al, 1989; Niort et al, 1992; Niort et al, 1995; Stewart et al, 1995). 
There was also a decrease in fibrinogen levels in our study. Previous studies 
have shown that bezafibrate produces a moderate to marked reduction in fibrinogen 
levels which is related to pretreatment values (Monk and Todd, 1987; Caimi et al, 
1988; Niort et al 1988; Pazzucconi et al, 1992; Branchi et al, 1993; Sinzinger et al, 
1995). 
All ofthese effects can help to prevent atherogenesis. This will help to reduce 
the development ofcoronary heart disease and may also improve glycaemic control in 
some groups of diabetic patients. Therefore, Bezafiirate is a good choice drug for the 
NIDDM patients with dyslipidaemia and for patients with elevated fibrinogen levels. 
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The blood pressure, liver function (apart from alkaline phosphatase, the 
significance of which is uncertain) and renal function did not significantly change 
after treatment with bezafibrate retard 400 mg once daily. In this study, there were no 
patient withdrawals during the study although some patients complained of fatigue, 
dizziness, swelling of feet or toes and shortness ofbreath after taking the drug so this 
drug appears to be well tolerated by Hong Kong patients of Chinese origin. 
In this study, a control run-in period of at least 6 weeks was included before 
active dmg treatment to stabilize the patients on diet to try to ensure that any changes 
during the treatment phase were really due to the drug therapy but we cannot entirely 
exclude a placebo effect as there was no parallel placebo control group and no cross-
over to placebo. 
7 
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Chapter 7 Discussion and Conclusions 
7.1. Introduction: the two study drugs, gemfibrozil and bezafibrate 
These two dmgs belong to the fibrate group of lipid-lowering dmgs. The fibrates 
includes clofibrate, ciprofibrate, gemfibrozil, fenofibrate and bezafibrate. They affect the 
expression of certain genes included in lipid metabolism. Liver fatty acid binding 
protein facilitates intracellular transport of fatty acids in aqueous compartments and 
influences fatty acid partitioning between esterifications and oxidation. Fibrates also 
increase the concentration and mRNA of this cytosolic protein by increasing gene 
transcription and acetyl-coA binding protein mRNA. (Asplund-Carlson, 1994.) Some 
fibrates have been found to markedly improve clearance of postprandial lipaemia and to 
reduce plasma fibrinogen, thereby reducing other cardiovascular risk factors. 
The main action of these lipid-lowering dmgs is on plasma triglycerides and 
triglyceride rich lipoprotein metabolism through a combination of effects consisting of 
decreased lipolysis in adipose tissue, inhibition of liver very low density lipoprotein 
(VLDL) synthesis or secretion and activation of lipoprotein lipase (LPL). Fibrates can 
increase HDL-C effectively even if the baseline triglyceride level is in the low range and 
the triglyceride may decrease to a value below the normal range (Davignon, 1994). 
However, they reduce de novo fatty acid synthesis in the liver by inhibition ofacetyl-coA 
carboxylase, the rate-limiting enzyme in fatty acid biosynthesis.(Davignon, 1994.) They 
also have a favorable affect on reverse cholesterol transport and increase the 
mitochondrial and peroxisomal fatty acid beta-oxidation in the liver due to activation of 
) 
specific nuclear receptors and they can improve glucose homeostasis in some 
circumstances. 
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Fibrinogen and other factors in the coagulation system are known to play a role in 
the development of atheroma and some of these factors have been identified as 
independent risk factors for CHD (Meade, 1995; Emst and Resch, 1993). Fibrates have 
an effect on coagulation because as well as fibrinogen they can affect factor VII, 
plasminogen activator inhibitor-I and tissue plasminogen activator and also alter platelet 
aggregation. 
The side effects of fibrates include an increased frequency of gallstones, upper 
gastrointestinal disturbances, headache, fatigue, myalgia, loss of libido and 
alopecia(Davignon, 1994: Goa et al, 1996). There are reports that fibrates can have 
carcinogenic potential in rodents and may also increase creatinine. 
7.2. Gemfibrozil 
The chemical structure of gemfibrozil is 5-(2,5-dimethylphenoxy)-2,2-dimethyl-
pentanoic acid.(Thompson, 1990.). It can decrease total cholesterol, triglycerides and 
LDL-cholesterol but increases HDL-cholesterol, apolipoprotein A and generally has no 
effect on lipoprotein(a) (Chisholm, 1993; Illingworth, 1993; Davignon, 1994). However, 
in patients with high triglycerides and low LDL-cholesterol, the LDL-cholesterol level 
may actually rise whereas with lower starting triglyceride levels the LDL-cholesterol 
often is reduced. The mechanism by which gemfibrozil effectively reduces triglycerides 
and increases the fractional clearance rate of triglyceride-rich lipoprotein occurs by 
activation of lipoprotein lipase. It can also reduce hepatic triglyceride synthesis by 
inhibition of lipase activity in adipose tissue leading to reduced mobilization and transfer 
i j 
to the liver of free fatty acids and it can inhibit their incorporation into triglyceride in the 
liver (Thompson, 1990.) 
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The elevation ofthe fractional clearance rate of triglyceride-rich lipoprotein is by 
raising LPL activity and activation of intravascular lipolysis which leads the surface 
components of chylomicrons and VLDL to be released to HDL particles and modify 
LDL particle composition with variation in the secondary structure of apolipoprotein B, 
thereby fully restoring the capacity of LDL particles to interact with the LDL receptor. 
The effect of gemfibrozil in reducing LDL-cholesterol concentrations may be related to 
inhibition of hydroxymethylglutaryl Coenzyme A (HMG CoA) reductase. It also 
reduces postprandial lipaemia in obese woman and hyperinsulinaemia leading to 
improved insulin sensitivity. It can also decrease factor VII-phospholipid complex and 
improve fibrinolytic capacity by inhibiting plasminogen activator inhibitor-1. 
The side effects of gemfibrozil include myopathy and gastrointestinal symptoms 
such as nausea, vomiting, abdominal discomfort and disturbance of bowel 
habit.(Thompson, 1990; Oberman, 1992) 
7.3. Bezafibrate 
The effects of bezafibrate are reduction of plasma triglyceride, total cholesterol, 
LDL-cholesterol, fibrinogen, viscosity and improvement in glucose tolerance in 
hypertriglyceridaemic patients and to increase the plasma HDL-cholesterol level. The 
mechanism is similar to that of gemfibrozil by stimulating the activity of lipoprotein 
lipase, and to a lesser extent, hepatic triglyceride lipase, promoting the catabolism of 
triglyceride-rich lipoproteins (Goa et al, 1996). It is believed that its action includes 
inhibition ofthe enzyme acetyl-coA carboxylase in the fatty acid synthesis pathway and 
it increases the activity of adipose tissue lipoprotein lipase (Thompson, 1990). It 
markedly reduces the semm triglyceride level in patients with type IV and IIb 
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phenotypes but elevations in LDL-cholesterol have been noticed in type IV patients 
(Betteridge, 1994). By stimulating receptor mediator FCR, bezafibrate can decrease 
LDL-cholesterol levels in hypercholesterolaemic patients. It can markedly improve 
glucose tolerance by reducing insulin resistance and the circulating levels of free fatty 
acids. In patients with renal failure, the half-life of this drug may be prolonged and this 
causes elevation ofplasma concentrations. The common side effects ofthis drug consist 
ofnausea, abdominal distention, impotence and myositis syndrome. 
7.4. Conclusion 
Hyperlipidaemia occurs when the blood lipids are outside the normal range. The 
different components of lipids have different normal values. The hyperlipidaemias have 
been classified into five types according to the different elevation of blood triglyceride, 
cholesterol or LDL-cholesterol. The causes of hyerlipidaemia have been divided into 
two main groups, one being the primary cause and the other group the secondary causes 
which relate to some diseases, drugs, hormone and toxins. 
Hyperlipidaemia can give rise to typical signs which may cause the doctor to 
suspect that the patient may suffer from hyperlipidaemia and symptoms which are 
mainly caused by the complications of hyperlipidaemia. Hyperlipidaemia is related to 
some diseases such as atherosclerosis, vascular insufficiency, hypertension, diabetes 
mellitus, thyroid disorders，liver disease, acute pancreatitis and renal diseases. 
In the three studies, the patients had stopped taking any lipid-lowering drugs for 
at least 6 weeks and followed the diet before the studies commenced. The clinical 
methods and laboratory methods which were used to monitor and assess the patients 
response to the drugs have been described. The clinical signs and symptoms were 
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recorded and blood was taken for laboratory analysis to measure the blood lipids, renal 
function, liver function and fasting blood glucose and the blood pressure level and body 
weight were measured every 4 weeks after the active treatment. 
From the results these three studies show that both gemfibrozil and bezafibrate 
were effective in reducing blood triglyceride levels and elevating blood HDL-cholesterol 
levels. These data are comparable with data available from Caucasians. However, they 
generally did not produce significant reduction of serum total cholesterol or LDL-
cholesterol levels. Neither drug showed significant efficacy in improving glycaemia in 
terms of effects on fasting blood glucose but bezafibrate was shown to decrease the 
fibrinogen level. Fibrinogen levels were not measured in the studies with gemfibrozil so 
no comparison of the drugs can be made for this effect. 
From the results of the gemfibrozil dose-titration study, it was found that 
gemfibrozil 300 mg twice daily was quite effective in many patients and higher doses 
had little further effect. Although there were some side effects with these three drug 
formulations, the patients in these studies, in general, tolerated these drugs very well. 
There were three patients who withdrew in the gemfibrozil titration study because of 
intolerance ofhigher doses of the dmg and there were also three patients withdrew in the 
gemfibrozil 900 mg once daily study due to intolerance to the side effects of the dmg. 
However, there were no withdrawals in the bezafibrate study although some patients 
complained ofmild side effects during the study but the side effects of this dmg appeared 
less than with gemfibrozil. ‘ 
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Side Effect Questionnaire 1 
Visit V I 
Name: Sex/Age: ID : Study no.  
Date 
• -
During the past month have you experienced any of the following symptoms or 
feelings? 對上的一個月你有沒有下列的症狀？ 
. . 
If any symptoms are present please indicate : 
Severity • 1. mld 2. moderate 3. severe 
Frequency i.e. number of tiroes per day or week 
Duration i.e. number of minutes, hours, days or constant 
and date of onset and termination 
Yes No Severity Frequency Pate 
S 否 and Onset End 
duration 
Headache 頭痛 _ _ — _ _ _ _ _ 
Dii2ine$s 域聚 _ _ _ _ _ 
Falntncs$ 待例 _ _ _ — _ 
Fallgue 疲" — 一 一 « _ 一 
Slecpiness 欲腿 _ _ .— _ _ 
flusMngWCTRtt _ — _ ^ _ _ 
Cold fingers tt tocs 
手0冰冷 _ — 一 _ _ 
Svelting of feet or ankles 
i9uum _ _ _ 一 _ 
t • 
Abnoml weight gain 
不正常的«3坊加 _ _ _ _ _ 
Bapia keattbcat 心！^姐速 一 一 一 _ 一 
Skfheartbeat6liltt^ _ _ _ _ _ 
Shortne$$ tf bteath 叙(S ._« 
Cough 咳揪 _ • _ 一 _ • • 一 
Sputura 较 — . _ _ 
Kausea tnd vonitIng 丨 
作租《吐 一 一 一_) — — 
Heartburn 打約热 _ -~<^  . _ _ _ 
Abdominal paln 议抜 一 — 一 ； ^ _ 
Constipation 使秘 
• . .• 
‘ : ‘ 
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*_i^SLS=^.^ .--:- '•• - •‘ - . • . - -• .-... . 
Side Effect Questionnaire 2 
Visit V I 
Name: Sex/Age: ID : Study no.  
Yes No Severity Frequency Date 
楚 S «nd Onset End 
duration 
r-"v ‘ ~~ ~ “ .* 
Diarrhoea HW  
“ I “ 胸 I I I “ • ~* •••"•^  ^mmm^ 
Skin nsh 皮 ?^ — 
tos9 cf taste 失去昧贷 — — — 
‘ ^ • ““ “‘ _ I _ • _ 
Halrlos$0KK^ _ „ _ _ _ 一 — 
try cye3 域乾 一 
Dry nx)uth 口 坊 ^_^ 
Blnrred vls!on 現力 t | 糊 _ _ _ _ _ _ 
• - -u 1 - - 「 • -i _ ‘ • ^ _ I11 _ - I 
Difficulty in rencobcring th!ngs 
K 域力 ^¾ a 一 一 — 
lnab!lity to concentrate 
狡 法 教 中 《 ” _ — 一 一 — 
Abnorne.l nwod stlngs tl f | 不定 
Dcpresscd "1^抑0 _ — _ 一 — 
Unable to fall isIeep 
沒法入《 / 
‘ I - • • • • * _ I _ r _ 
Kurnbncs$ or tin&1ing in hands/feet 
手0財木/«痛 一 „ 一 
Kightvaie9 fi U 砂  
laVlng t)p duiing n!ght 
在 晚 上 0 來 — — _ _ _ _ _ — 
Increased frcquency cf urination 
紹尿 — _ _ _ 一 
Impotence 丨5资 一 — 一 — — 
Docreased interest in 8ex 
性《减这 一 — _ _ — 
Muscle cnunp$ 肌肉抽筋 _ _ 
Stiffne$3 in vuscles 
肌 肉 « « _ 
~ ~ - ~ — ‘ — - — * " ^ - . — 
Difficulty nlkin3 
行動困较 _ 一 _ — — 
Signature • * Dat^ … 
lll ^ ^ J ^ i ^ ^ ^ l ^ J ^ H 4 s i ^ l
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